Solanesol Market Potential Growth, Share, Demand And Analysis Of Key Players- Research Forecasts To 2026| ExtRx, Zhejiang Yixin Pharmaceutical,…

LOS ANGELES, United States: The global Solanesol market is carefully researched in this report, keeping in view important aspects such as market competition, global and regional growth, market segmentation, and market structure. The analysts authoring the report have estimated the size of the global Solanesol market in terms of value and volume with the use of latest research tools and techniques. The report also includes estimations of market shares, revenue, production, consumption, gross margin, CAGR, and other key factors. Readers can expand their knowledge of business strategies, recent developments, and current as well as future progress of leading players of the global Solanesol market.

Get Full PDF Sample Copy of Report: (Including Full TOC, List of Tables & Figures, Chart) https://www.qyresearch.com/sample-form/form/1776151/1535187/global-solanesol-market-report-history-forecast

Besides a dashboard view of the vendor landscape and important company profiles, the competitive analysis offers an encyclopedic examination of the market structure. The company share analysis included in this study helps players to improve their business tactics and compete well against leading market participants. The intensity map prepared by our analysts helps to get a quick view of the presence of several players in the global Solanesol market. The report also provides a footprint matrix of key players of the global Solanesol market. It dives deep into growth strategies, sales footprint, production footprint, and product and application portfolios of prominent names of the industry.

Key Players Mentioned in the Global Solanesol Market Research Report: ExtRx, Zhejiang Yixin Pharmaceutical, Sanming Huajian Bioengineering

Global Solanesol Market by Type: 90% Solanesol, 95% Solanesol

Global Solanesol Market by Application: Coenzyme Q10, Vitamin K2, Other

The report includes a deep segmentation study of the global Solanesol market, where both segments and sub-segments are analyzed in quite some detail. This study will help players to concentrate on high-growth segments and modify their business strategies, if required. The global Solanesol market is segmented on the basis of type, application, and geography. The regional segmentation study offered in the report equips players with useful information and data related to important geographical markets such as North America, China, Europe, India, the U.S., the U.K., and the MEA. Our researchers and analysts use reliable primary and secondary sources for research and data.

Critical Questions Addressed by the Report

Request for customization in Report: https://www.qyresearch.com/customize-request/form/1535187/global-solanesol-market-report-history-forecast

Table of Contents

About Us:

QY Research established in 2007, focus on custom research, management consulting, IPO consulting, industry chain research, data base and seminar services. The company owned a large basic data base (such as National Bureau of statistics database, Customs import and export database, Industry Association Database etc), experts resources (included energy automotive chemical medical ICT consumer goods etc.

More:
Solanesol Market Potential Growth, Share, Demand And Analysis Of Key Players- Research Forecasts To 2026| ExtRx, Zhejiang Yixin Pharmaceutical,...

COVID-19 Impact ON Processed Food & Beverage Preservatives Market Size and CAGR by Regional Forecast by 2020-2026 | Celanese Corporation,…

The globalProcessed Food & Beverage Preservatives Marketis carefully researched in the report while largely concentrating on top players and their business tactics, geographical expansion, market segments, competitive landscape, manufacturing, and pricing and cost structures. Each section of the research study is specially prepared to explore key aspects of the global Processed Food & Beverage Preservatives market. For instance, the market dynamics section digs deep into the drivers, restraints, trends, and opportunities of the global Processed Food & Beverage Preservatives market. With qualitative and quantitative analysis, we help you with thorough and comprehensive research on the global Processed Food & Beverage Preservatives market. We have also focused on SWOT, PESTLE, and Porters Five Forces analyses of the global Processed Food & Beverage Preservatives market.

Leading players of the global Processed Food & Beverage Preservatives market are analyzed taking into account their market share, recent developments, new product launches, partnerships, mergers or acquisitions, and markets served. We also provide an exhaustive analysis of their product portfolios to explore the products and applications they concentrate on when operating in the global Processed Food & Beverage Preservatives market. Furthermore, the report offers two separate market forecasts one for the production side and another for the consumption side of the global Processed Food & Beverage Preservatives market. It also provides useful recommendations for new as well as established players of the global Processed Food & Beverage Preservatives market.

Request sample copy of this report:https://www.reporthive.com/request_sample/2294008

Major Players:

Celanese CorporationKoninklijke DSM N.V.E.I.du Pont de Nemours and CompanyKerry Group PlcGalactic SAHawkins Watts LimitedInnophos Holdings IncKemin Industries, IncCargill, IncorporatedAkzo Nobel N.V.Albemarle CorporationNaturalin Bio-Resources Co., LtdShandong Kunda Biotechnology Co., LtdShanghai Ruidian Trading Development Co.Ecochem Group Co., LtdNingbo Pangs Chem Intl Co., Ltd.Zhejiang Silver Elephant Bioengineering Co., Ltd.Shandong Tong Tai Wei Run Chemical Co., LtdLaiwu Taihe Biochemistry Co., LtdSEEBIO BIOTECH (SHANGHAI) CO.,LTD

Segmentation by Product:

NaturalBenzoatesNitritesSulfiteSorbates/Propionates

Segmentation by Application:

BakeryConfectioneryMeat, Poultry & Sea FoodDairyBeverages/Snack Food/Frozen Food/Fats and Oils

Regions and Countries:U.S, Canada, France, Germany, UK, Italy, Rest of Europe, India, China, Japan, Singapore, South Korea, Australia, Rest of APAC, Brazil, Mexico, Argentina, Rest of LATAM, Saudi Arabia, South Africa, UAE.

Report Objectives

Table of Contents

Report Overview:It includes major players of the global Processed Food & Beverage Preservatives market covered in the research study, research scope, and Market segments by type, market segments by application, years considered for the research study, and objectives of the report.

Global Growth Trends:This section focuses on industry trends where market drivers and top market trends are shed light upon. It also provides growth rates of key producers operating in the global Processed Food & Beverage Preservatives market. Furthermore, it offers production and capacity analysis where marketing pricing trends, capacity, production, and production value of the global Processed Food & Beverage Preservatives market are discussed.

Market Share by Manufacturers:Here, the report provides details about revenue by manufacturers, production and capacity by manufacturers, price by manufacturers, expansion plans, mergers and acquisitions, and products, market entry dates, distribution, and market areas of key manufacturers.

Market Size by Type:This section concentrates on product type segments where production value market share, price, and production market share by product type are discussed.

Market Size by Application:Besides an overview of the global Processed Food & Beverage Preservatives market by application, it gives a study on the consumption in the global Processed Food & Beverage Preservatives market by application.

Production by Region:Here, the production value growth rate, production growth rate, import and export, and key players of each regional market are provided.

Consumption by Region:This section provides information on the consumption in each regional market studied in the report. The consumption is discussed on the basis of country, application, and product type.

Company Profiles:Almost all leading players of the global Processed Food & Beverage Preservatives market are profiled in this section. The analysts have provided information about their recent developments in the global Processed Food & Beverage Preservatives market, products, revenue, production, business, and company.

Market Forecast by Production:The production and production value forecasts included in this section are for the global Processed Food & Beverage Preservatives market as well as for key regional markets.

Market Forecast by Consumption:The consumption and consumption value forecasts included in this section are for the global Processed Food & Beverage Preservatives market as well as for key regional markets.

Value Chain and Sales Analysis:It deeply analyzes customers, distributors, sales channels, and value chain of the global Processed Food & Beverage Preservatives market.

Key Findings:This section gives a quick look at important findings of the research study.

Request for Customization:https://www.reporthive.com/request_customization/2294008

About us:

Our research base consists of a wide spectrum of premium market research reports. Apart from comprehensive syndicated research reports, our in-house team of research analysts leverages excellent research capabilities to deliver highly customized tailor-made reports. The market entry strategies presented in our reports has helped organizations of all sizes to generate profits by making timely business decisions. The research information including market size, sales, revenue, and competitive analysis offered, is the product of our excellence in the market research domain.

Link:
COVID-19 Impact ON Processed Food & Beverage Preservatives Market Size and CAGR by Regional Forecast by 2020-2026 | Celanese Corporation,...

The Commons announces shift to virtual format for Red Hot [Remote] Research in fall 2020 – KU Today

LAWRENCE Red Hot Research will return this fall in a different setting. The series, sponsored by The Commons at the University of Kansas, will take place over Zoom and feature most of the trademark elements of the traditional in-person event as it shifts to a digital channel for connecting scholars to their peers across disciplines.

Red Hot [Remote] Research will continue as a regular Friday event, beginning at 4 p.m. and featuring research from disciplines across the university around core themes. Each session will feature five presenters sharing short talks on an area of focus within their work. The series will continue to open the door for new ways of understanding work through discussion across perspectives.

The first event is scheduled for 4 p.m. Sept. 18 and will focus on Care & Aging. Subsequent sessions are scheduled for Oct. 9 on Rural/Urban, Oct. 23 on Gender & Representation and a special session Oct. 28, hosted in conjunction with a series of events KU has planned to celebrate the 30th anniversary of the Americans with Disabilities Act (ADA).

Additionally, one Red Hot Graduate Research session, an opportunity for graduate students to share their work with colleagues across campus, will be presented remotely Nov. 20.

In keeping with the goals of this series, presenters are asked to consider how other disciplinary perspectives could contribute to their research, the likely next steps for the research and challenges that they face in conducting the research. In turn, audience members are asked to, from their own perspectives, offer insights, questions and ideas.

Check The Commons website for Zoom registration information: https://thecommons.ku.edu/coming-events

Sept. 18: Care & Aging

Oct. 9: Rural / Urban

Emcee: Dave Tell, professor of communication studies and co-director of the Institute for Digital Research in the Humanities

Oct. 23: Gender & Representation

Oct. 28: Disability Studies

Emcee: Dot Nary, assistant research professor, Research & Training Center on Independent Living

Nov. 20: Graduate Research

Emcee: Elise Higgins, doctoral student in women, gender & sexuality studies.

See the article here:
The Commons announces shift to virtual format for Red Hot [Remote] Research in fall 2020 - KU Today

Trending News Corona Impact On 2020-2026 Mini Bioreactor Market Report 2020-2026 Includes Analysis To Product Type| Major Application| Key Regions|…

Chicago, United States:The global 2015-2025 Mini Bioreactor Market report offers a complete research study that includes accurate estimations of market growth rate and size for the forecast period 2020-2025. It offers a broad analysis of market competition, regional expansion, and market segmentation by type, application, and geography supported by exact market figures. The all-inclusive market research report also offers Porters Five Forces Analysis and profiles some of the leading players of the global 2015-2025 Mini Bioreactor Market. It sheds light on changing market dynamics and discusses about different growth drivers, market challenges and restraints, and trends and opportunities in detail. Interested parties are provided with market recommendations and business advice to ensure success in the global 2015-2025 Mini Bioreactor Market.

Top Key players cited in the report:Thermo Fisher, Merck KGaA, Danaher (Pall), GE Healthcare, Sartorius AG (BBI), ZETA, Eppendorf AG, Pierre Guerin (DCI-Biolafitte), Praj Hipurity Systems, Bioengineering AG, Infors HT, Applikon Biotechnology, Solaris

Get Free PDF Sample Copy of this Report to understand the structure of the complete report: (Including Full TOC, List of Tables & Figures, Chart): https://www.reporthive.com/request_sample/2396916

The final report will add the analysis of the Impact of Covid-19 in this report 2015-2025 Mini Bioreactor Market

2015-2025 Mini Bioreactor Marketreports offers important insights which help the industry experts, product managers, CEOs, and business executives to draft their policies on various parameters including expansion, acquisition, and new product launch as well as analyzing and understanding the market trends.

Each segment of the global 2015-2025 Mini Bioreactor market is extensively evaluated in the research study. The segmental analysis offered in the report pinpoints key opportunities available in the global 2015-2025 Mini Bioreactor market through leading segments. The regional study of the global 2015-2025 Mini Bioreactor market included in the report helps readers to gain a sound understanding of the development of different geographical markets in recent years and also going forth. We have provided a detailed study on the critical dynamics of the global 2015-2025 Mini Bioreactor market, which include the market influence and market effect factors, drivers, challenges, restraints, trends, and prospects. The research study also includes other types of analysis such as qualitative and quantitative.

Global 2015-2025 Mini Bioreactor Market: Competitive Rivalry

The chapter on company profiles studies the various companies operating in the global 2015-2025 Mini Bioreactor market. It evaluates the financial outlooks of these companies, their research and development statuses, and their expansion strategies for the coming years. Analysts have also provided a detailed list of the strategic initiatives taken by the 2015-2025 Mini Bioreactor market participants in the past few years to remain ahead of the competition.

Global 2015-2025 Mini Bioreactor Market: Regional Segments

The chapter on regional segmentation details the regional aspects of the global 2015-2025 Mini Bioreactor market. This chapter explains the regulatory framework that is likely to impact the overall market. It highlights the political scenario in the market and the anticipates its influence on the global 2015-2025 Mini Bioreactor market.

Request For Customization:https://www.reporthive.com/request_customization/2396916

Report Highlights

Table of Contents

Report Overview:It includes six chapters, viz. research scope, major manufacturers covered, market segments by type, 2015-2025 Mini Bioreactor market segments by application, study objectives, and years considered.

Global Growth Trends:There are three chapters included in this section, i.e. industry trends, the growth rate of key producers, and production analysis.

2015-2025 Mini Bioreactor Market Share by Manufacturer:Here, production, revenue, and price analysis by the manufacturer are included along with other chapters such as expansion plans and merger and acquisition, products offered by key manufacturers, and areas served and headquarters distribution.

Market Size by Type:It includes analysis of price, production value market share, and production market share by type.

Market Size by Application:This section includes 2015-2025 Mini Bioreactor market consumption analysis by application.

Profiles of Manufacturers:Here, leading players of the global 2015-2025 Mini Bioreactor market are studied based on sales area, key products, gross margin, revenue, price, and production.

2015-2025 Mini Bioreactor Market Value Chain and Sales Channel Analysis:It includes customer, distributor, 2015-2025 Mini Bioreactor market value chain, and sales channel analysis.

Market Forecast Production Side: In this part of the report, the authors have focused on production and production value forecast, key producers forecast, and production and production value forecast by type.

Get Free Sample Copy of this report:https://www.reporthive.com/request_sample/2396916

About Us:Report Hive Research delivers strategic market research reports, statistical survey, and Industry analysis and forecast data on products and services, markets and companies. Our clientele ranges mix of United States Business Leaders, Government Organizations, SMEs, Individual and Start-ups, Management Consulting Firms, and Universities etc. Our library of 600,000+ market reports covers industries like Chemical, Healthcare, IT, Telecom, Semiconductor, etc. in the USA, Europe Middle East, Africa, Asia Pacific. We help in business decision-making on aspects such as market entry strategies, market sizing, market share analysis, sales and revenue, technology trends, competitive analysis, product portfolio and application analysis etc.

More:
Trending News Corona Impact On 2020-2026 Mini Bioreactor Market Report 2020-2026 Includes Analysis To Product Type| Major Application| Key Regions|...

Bacillus Subtilis Market with Forecast , Organization Sizes, Top Vendors, Industry Research and End User Analysis By 2027 – The Daily Chronicle

The Bacillus Subtilis Market Research Report is a resource, which provides current as well as upcoming technical and financial details of the industry to 2027. This report gives you so important and essentials data of Market size, share, trends, Growth, applications, forecast and cost analysis. Delivery development in North America, China, Europe, and South East Asia, Japan as well as in the Globe. The report proves to be indispensable when it comes to market definition, classifications, applications and engagements. The market report also computes the market size and revenue generated from the sales. The industry analysis report presents the key statistics on the market status of global and regional manufacturers and also acts as a valuable source of leadership and direction. What is more, theBacillus Subtilis market report analyses and provides historic data along with the current performance of the market.

This Press Release will help you to Know the Volume, growth with Impacting Trends. Get SAMPLE PDF (Including Full TOC, Table & Figures) at:

Get Free PDF Brochure Of this Research Report @ https://www.coherentmarketinsights.com/insight/request-pdf/1253

Global Bacillus Subtilis Market competition by Top Key Players: Bayer AG, BASF SE, Jocanima Corporation, Tonglu Huifeng, Kernel Bio-tech, Wuhan Natures Favour Bioengineering Co., Ltd., Real IPM, ECOT China, and Qunlin..

Bacillus Subtilis Market section by Region:

The Middle East and Africa North AmericaSouth AmericaEuropeAsia-Pacific

Segmentation: The report has been separated into different categories, such as product type, application, end user, and region. Every segment is evaluated based on the CAGR, share and growth potential. In the regional analysis, the report highlights the prospective region, which should generate opportunities in the global Bacillus Subtilis market in the years to come. This segmented analysis will surely prove to be a useful tool for readers, stakeholders and market participants to get a full picture of the Bacillus Subtilis global market and its growth potential in the years to come.

TheBacillus SubtilisMarket report offers a plethora of insights which include:

Get Your Copy at a Discounted Rate!!! Limited Time Offer!!! : https://www.coherentmarketinsights.com/insight/request-discount/1253

Important Information that can be extracted from the Report:

Assessment of the COVID-19 impact on the growth of the Bacillus Subtilis MarketSuccessful market entry strategies formulated by emerging market playersPricing and marketing strategies adopted by established market playersCountry-wise assessment of the Bacillus Subtilis Market in key regionsYear-on-Year growth of each market segment over the forecast period 2027

TheBacillus SubtilisMarket report considers the following years to predict market growth:

The GlobalBacillus SubtilisMarket is displayed in 13 Chapters:

Chapter 1: Market Overview, Drivers, Restraints and OpportunitiesChapter 2: Market Competition by ManufacturersChapter 3: Production by RegionsChapter 4: Consumption by RegionsChapter 5: Production, By Types, Revenue and Market share by TypesChapter 6: Consumption, By Applications, Market share (%) and Growth Rate by ApplicationsChapter 7: Complete profiling and analysis of ManufacturersChapter 8: Manufacturing cost analysis, Raw materials analysis, Region-wise manufacturing expensesChapter 9: Industrial Chain, Sourcing Strategy and Downstream BuyersChapter 10: Marketing Strategy Analysis, Distributors/TradersChapter 11: Market Effect Factors AnalysisChapter 12: Market ForecastChapter 13:Bacillus Subtilis Research Findings and Conclusion, Appendix, methodology and data source

See original here:
Bacillus Subtilis Market with Forecast , Organization Sizes, Top Vendors, Industry Research and End User Analysis By 2027 - The Daily Chronicle

AI-based brain monitoring and robotic muscle projects win 11.5m EPSRC boost | Imperial News – Imperial College London

Two Imperial College London projects have won a total of 11.5 million to transform healthcare technologies by 2050.

The UKRI EPSRC Transformative Healthcare Technologies for 2050 funding aims to foster the development of revolutionary new technological approaches to transform care and treatments in the NHS by 2050.

A new Imperial-led project will monitor the brain in a way never achieved before.

The project team, led by Professor Dario Farina at the Department of Bioengineering, will develop a new technology, known as Non-Invasive Single Neuron Electrical Monitoring (NISNEM), with the aim of helping scientists better understand neurological diseases like stroke and Parkinsons.

The researchers hope the technology will enable new neurotechnology-based treatments that are non-invasive and more effective than current ones.

Current approaches to monitoring the brain, like using surgical implants, are invasive. However, NISNEM technology uses electrical signals recorded on the skin surface from extremely high-density electrode probes to create images of the brain, which AI algorithms then scan to find traces of individual neuron activities. These decoded neural activities could reveal signs of neurological impairments like stroke and Parkinsons, and help drive brain-computer interfaces for assistance and therapy.

Stroke affects more than more than 100,000 people per year in the UK, and occurs when the supply of blood to the brain is reduced or blocked. It most commonly arises in the cerebral artery, which directly affects the motor cortex, and can cause substantial impairments in the motor abilities of patients affecting walking and speech.

Parkinsons disease affects 1 in 500 people, causing parts of the brain to become progressively damaged over many years. It develops when dopamine-producing cells in the brain stop working properly and are lost over time. This causes a lack of dopamine in the brain, which is important for movement and speech, and causes tremor, slowness of movement, and muscle stiffness.

Stroke and Parkinsons are only two examples of the impairments targeted by the new NISNEM technology. The researchers hope the new technology will detect brain abnormalities to help early diagnosis of these progressive diseases as well as developing non-invasive treatments.

Professor Farina said: The current inability to access single neuron activity in the brain not only limits our ability to understand and diagnose neurological conditions, but also prevents the broad adoption of neurotechnologies in healthcare. We hope our technology, funded by the EPSRC grant, will provide a breakthrough in understanding, diagnosing, and treating increasingly prevalent neurological conditions, such as stroke, Parkinsons disease, and Alzheimers.

A University of Bristol-led project involving Imperials Professor Molly Stevens aims to develop artificial robotic muscular assistance to help restore strength in people who have lost muscle capability. This could include patients who have suffered a stroke or are living with degenerative diseases such as sarcopenia and muscular dystrophy.

Using these highly targeted robotics could help overcome the limitations of current wearable assistive technologies in regenerative medicine. Often, these technologies can be bulky and uncomfortable to wear, and can require two people to put on and take off. Users can also find the movements too slow.

Through using robots to boost the performance of such technologies, the project, called emPOWER, could provide life-changing benefits for sufferers by restoring their confidence, independence and quality of life - all while reducing the cost to the NHS.

Co-investigator Professor Stevens of the Department of Materials said: Loss of strength and muscle wastage is currently an unenviable part of getting older and has a significant impact on health and quality of life. emPOWER will explore how artificial muscles could radically transform treatment options in the future and effectively turn back the body clock.

emPOWER is led by Professor Jonathan Rossiter at Bristol, in partnership with Imperial, UCL and the NIHR Devices for Dignity MedTech Co-operative, hosted by Sheffield Teaching Hospitals Foundation Trust.

Science minister Amanda Solloway announced the funding as part of her keynote speech at London Tech Week 2020.

She said: The pioneering projects we are backing today will help modernise healthcare, improving all of our lives now and into the future. This announcement is part of our ambitious R&D Roadmap and underlines our commitment to back our incredible scientists and researchers and invest in ground-breaking research to keep the UK ahead in cutting-edge discoveries.

View post:
AI-based brain monitoring and robotic muscle projects win 11.5m EPSRC boost | Imperial News - Imperial College London

Smart Grid Market Trends and Opportunities by Product Types and Application In Grooming Regions, By 2020 – The Daily Chronicle

The report on global Smart Grid market 2020-25 is a systematic compilation, lending in crucial understanding and insights touching upon various parameters of the market such as market share, segment analysis, geographical distribution as well as vendor assessment to ensure profit driven business decisions in global Smart Grid market.

Acknowledge the Global Smart Grid market with the assist of our expert analyst moderating the worldwide fluctuations. This market report will answer all your queries regarding growth of your business in this Covid-19 pandemic.

Top Leading Key Players are:

ABB, Cisco, General Electric, Honeywell, Eaton, Itron, Oracle, Schneider Electric, Siemens, Wipro

Get Sample PDF (including COVID19 Impact Analysis, full TOC, Tables and Figures) of Smart Grid Market @ https://www.adroitmarketresearch.com/contacts/request-sample/259

COVID-19 Specific Analysis: Global Smart Grid Market

This elaborate presentation on global Smart Grid market also incorporates excerpts from the COVID-19 pre and post assessment that have imposed massive alterations in market dynamics spectrum. The report is designed to align with reader preferences to emerge from the downward growth trail. A close review of all-important factors and developments concurrent in global Smart Grid market have been closely reviewed in this section to enable novel investment decisions.

Post recurrent primary and secondary research endeavors by our in-house expert researchers, the global Smart Grid market is anticipated to nail a moderately decent growth with a valuation of xx million US dollars in 2020. Further, research also suggests growth probability of xx million USD through the forecast span, 2020-27, clocking in a healthy CAGR of xx% during this period.

Sectional Representation: Global Smart Grid Market

*In-depth analysis of leading market manufacturers, complete with their product and service portfolios along with details on revenue generation and overall sales have been minutely assessed in the report for the period, 2020-25

*References of the leading, growth inclusive regions have been entailed in the report. Minute details on sales performance, market share and revenue generation milestones are contained in the report with reference to regions and country-wise specifications as well.

*Elaborate details on other market relevant information comprising sales channels and supply chain management. The report includes details on sales channels, traders, distributors as well as dealers in the chain.

*Excerpts on market relevant information entailing growth scope, market size expansion, risk assessment as well as other notable drivers and factors are presented

*Details pertaining to new investment projects as well as vital research conclusions along with their feasibility have been touched upon in this section of the report.

Browse the complete report Along with TOC @ https://www.adroitmarketresearch.com/industry-reports/smart-grid-technology-market

Global Smart Grid Market is segmented based by type, application and region.

Based on Type, the Market has been segmented into:

By Solution (Advanced Metering Infrastructure,Smart Grid Distribution Management,Smart Grid Communications,Smart Grid Network Management,Substation Automation,Smart Grid Security,Others) , By End Use (Residential,Commercial,Industrial)

Based on application, the Market has been segmented into:

By Application (Generation,Transmission,Distribution,Consumption)

Smart Grid Market Regions and Countries Level Analysis

Regional analysis is a highly comprehensive part of this report. This segmentation sheds light on the sales of the Smart Grid on regional- and country-level. This data provides a detailed and accurate country-wise volume analysis and region-wise market size analysis of the global market.

The report offers an in-depth assessment of the growth and other aspects of the market in key countries including the US, Canada, Mexico, Germany, France, the UK, Russia, Italy, China, Japan, South Korea, India, Australia, Brazil, and Saudi Arabia.

The competitive landscape chapter of the global market report provides key information about market players such as company overview, total revenue (financials), market potential, global presence, Smart Grid sales and revenue generated, market share, prices, production sites and facilities, products offered, and strategies adopted.

This study provides Smart Grid sales, revenue, and market share for each player covered in this report for a period between 2020 and 2025.

Report Investment: Know the Pros

oBesides assessing real time developments and triggers, this section of the report also presents notable past highlights that accelerated growth in global Smart Grid market.

oA well scouted presentation of all the crucial segments that collectively harness maximum profit building in global Smart Grid market

oA detailed account of crucial market developments, potential investment bays as well as evaluation of successful business decisions that guide profitable business outcome

oA clear depiction of market specific dynamics, competitor analysis as well as gauging competition intensity

About Manufacturers and Growing Competition

* The report shares crucial details on specific areas comprising a close analytical review of competition spectrum.

* Each of the frontline players is thoroughly identified and profiled in the report, followed by a systematic profiling of their product portfolio as well as company status and portfolio against neck deep competition in the Master Smart Grid market.

* Further, the report also considers various growth nurturing practices and tactical business decisions undertaken by the profiled frontline players to secure seamless stance in the Master Smart Grid market despite sharp competition.

* The report is a complete representation of all the major initiatives initiated by various market players across diverse geographical hubs and their consequent implications upon consumer preferences and behavior.

* The report also enumerates various short- and long-term goals of the key players.

For Any Query on the Smart Grid Market @ https://www.adroitmarketresearch.com/contacts/enquiry-before-buying/259

About Us :

Adroit Market Research is an India-based business analytics and consulting company incorporated in 2018. Our target audience is a wide range of corporations, manufacturing companies, product/technology development institutions and industry associations that require understanding of a Markets size, key trends, participants and future outlook of an industry. We intend to become our clients knowledge partner and provide them with valuable Market insights to help create opportunities that increase their revenues. We follow a code- Explore, Learn and Transform. At our core, we are curious people who love to identify and understand industry patterns, create an insightful study around our findings and churn out money-making roadmaps.

Contact Us :

Ryan JohnsonAccount Manager Global3131 McKinney Ave Ste 600, Dallas,TX75204, U.S.A.Phone No.: USA: +1 972-362 -8199/ +91 9665341414

See the original post:
Smart Grid Market Trends and Opportunities by Product Types and Application In Grooming Regions, By 2020 - The Daily Chronicle

The Recovery Room: News beyond the pandemic – Medical News Today

September 18 The coronavirus pandemic has dominated the headlines and our daily lives for most of this year. Medical News Today have covered this fast-moving, complex story with live updates on the latest news, interviews with experts, and an ongoing investigation into the deep racial disparities that COVID-19 has helped unmask.

However, this has not stopped us from publishing hundreds of fascinating stories on a myriad of other topics.

This week, were very pleased to unwrap the first installment of our Curiosities of Medicine series, which is all about how human remains have played a part in medicine down the ages. For both this series and our Medical Myths series, MNT will continue to cover the darker and more unexpected side of medicine.

We also take another look at the central role of vitamin D in human health this week, in older males. As we reported this week, you might also increase your chances of enjoying old age by cutting out ultra-processed foods, reducing your calorie intake, or taking a drug that mimics calorie restriction.

Finally, we round off this weeks Recovery Room with news of a possible treatment for muscular dystrophy and an explanation of why a babys smile may not mean that theyre happy.

Below are 10 recent stories that people may have missed amid all the COVID-19 fervor.

This week, MNT published the first article in a new series examining medical curiosities. In this Special Feature, author Maria Cohut, Ph.D., takes a look at the macabre practice of medical cannibalism, focusing on the preparation and ingestion of mumia, or mummy powder.

Mumia featured in European medicine for hundreds of years as a treatment for pain, inflammation, and coughing. People also used it for wound healing, blood thinning, and many other purposes.

However, there were constant worries about whether or not mumia had actually been sourced from local and recent donors rather than real Ancient Egyptian mummies.

The article is a fascinating exploration of a dark and unusual chapter of medical history. We eagerly await the next in the series.

Learn more here.

This report on a breakthrough in the measurement of free metabolites of vitamin D and their role in predicting future health quickly emerged as our most popular article this week.

Experts have long known vitamin D to play a central role in human health. They have linked low levels to an increased risk of osteoporosis, cancer, cardiovascular disease, and cognitive decline. This new research uses a novel measure of two types of vitamin D to forecast the risk of death rather than to establish an association after the fact.

Learn more here.

Our report on the link between anticholinergic medications and mild cognitive impairment, which can lead to dementia, was also very widely read this week. The article has attracted more than 42,000 page views on the MNT website since Wednesday.

Researchers describe the effects of these drugs as a double hit on people who are already genetically susceptible to Alzheimers disease.

Learn more here.

Ultra-processed foods (UPFs) are tasty, inexpensive, and widely available. Theyre also nutritionally poor and contain high levels of additives, sugar, fat, and salt. Research links UPFs to serious conditions, such as obesity, metabolic syndrome, and some types of cancer.

A newly published study shows that a diet high in UPFs may contribute to biological aging processes at the cellular level. The researchers found a clear correlation between the level of UPF consumption and reduced telomere length. Eating more foods high in UPFs also had links to depression, hypertension, and all-cause mortality.

Learn more here.

MNT recently published an investigation into the science of sleep, featuring articles on dreaming, sleep disorders, and how to get a good nights rest. This week, we reported on how sleep might have a less significant role than previously thought when it comes to clearing metabolic waste products from the brain.

The glymphatic system takes out the brains trash, but new research highlights the role of the body clock in controlling this system. People who are not able to sleep at a regular time or who sleep during the day because of shift work may be at additional risk of developing neurological conditions as a result.

Learn more here.

Research shows that laboratory animals eating a calorie restricted diet live longer and are less likely to suffer diseases of older age, such as cancer and heart disease. It seems likely that humans would also benefit in this way from eating fewer calories, but it is very difficult for most people to stick to such a diet over a lifetime.

This week, we reported on research that used artificial intelligence to identify which new drugs could effectively mimic calorie restriction without the need for a person to maintain a significantly calorie restricted diet.

Learn more here.

Sexual desire in males is not all about testosterone. A recent mouse study investigating the role of aromatase in the brain found that the enzyme plays an important role in sexual activity in males.

In mice that had no aromatase in their brains, sexual activity reduced by half, despite these mice having higher levels of testosterone than those in the control group. Mice that could not produce aromatase anywhere in their body showed no sexual activity at all.

Learn more here.

Are antianxiety medications targeting the wrong system? Most anxiety treatments work on the nervous system but do not offer permanent relief from symptoms. This week, MNT reported on a small-scale study linking anxiety disorders to inflamed thyroid glands, which are part of the endocrine system.

If further investigation confirms this discovery, new treatment options may become available for the estimated 264 million people around the world who suffer from anxiety disorders. Nonsteroidal anti-inflammatory drugs such as ibuprofen, which the researchers used in this study, are cheap and widely available.

Learn more here.

There is currently no cure for Duchenne muscular dystrophy (DMD), a genetic disease that reduces life expectancy to an average of 26 years. However, this week, MNT reported on a potential new treatment.

Researchers at Yale University screened more than 160,000 compounds to find a molecule that blocks an enzyme, MKP5, which is known to destroy muscle tissue in people with DMD.

Scientists had considered MKP5 undruggable, but the new compound potently and selectively inhibits the enzyme. The compound may also be a candidate drug for other conditions that involve tissue scarring, including chronic liver disease.

Learn more here.

As well as covering the latest medical news and research, MNTs editorial team works tirelessly to answer thousands of questions that people may have about their health and that of their family members. We published a classic example this week our article on babies and their smiles.

A babys earliest smiles are reflex smiles. They will usually develop real smiles, signaling contentment, between 6 and 12 weeks of age. This article looks at why and when babies start to smile. It also explains when to see a doctor.

Learn more here.

We hope that this has provided a taste of the range of stories that we cover at MNT. We will be back with a new selection next week.

We publish hundreds of new articles every month. Here are some upcoming articles that may pique our readers interest:

Read the original here:
The Recovery Room: News beyond the pandemic - Medical News Today

Helixmith eyeing P3-3 clinical trials of gene therapy Engensis – Korea Biomedical Review

Helixmith said Wednesday that it has submitted a phase 3-3 extension study protocol of its gene therapy Engensis (VM202) for diabetic peripheral neuropathy (DPN), to the U.S. Food and Drug Administration.

The company set a one-year follow-up period to confirm the pain reduction and safety of VM202 in treating DPN. DPN is one of the most common complications of diabetic diseases. About 30 million Americans have diabetes, and 28.5 percent of them develop DPN. Among the DPN patients, 40 to 50 percent experience painful symptoms.

The study's primary endpoint is the average pain reduction effect measured and recorded in the pain diary over the last week of the sixth month from the first injection.

The study will be carried out with patients who had not taken Gabapentinoids, such as Pregabalin and Gabapentine, in 15 research laboratories across the U.S., including Northwestern University in Chicago.

"Existing painkillers for DPN patients are not a fundamental treatment for the disease as they only relieved pain while often accompanying serious side effects and high addiction," Helixmith CEO Kim Sun-young said. "We will try our best for the success of phase 3-3 clinical trials as well as the ongoing phase 3-2 study."

FDA recognized the clinical results of Engennsis and designated it as an advanced regenerative medicine advanced therapy (RMAT) in 2018, the company said. RMAT is a new system designed to speed up the development and approval of innovative regenerative therapies. It gives special privileges of the U.S. fast track and priority or accelerated screening.

View original post here:
Helixmith eyeing P3-3 clinical trials of gene therapy Engensis - Korea Biomedical Review

Capmatinib Shows Clinical Activity in MET Exon 14Mutated NSCLC – Cancer Therapy Advisor

Oral MET inhibitor capmatinib showed clinical activity in patients with MET exon 14mutated advanced nonsmall cell lung cancer (NSCLC), including those with brain metastases. The results of the phase 2 GEOMETRY mono-1 trial were recently published in the New England Journal of Medicine.

The trial (ClinicalTrials.gov Identifier: NCT02414139) included 364 patients with MET-dysregulated advanced NSCLC who were grouped into cohorts on the basis of prior lines of therapy and MET status (MET exon 14 skipping mutation or number of MET amplification gene copy numbers).

Among patients with MET exon 14mutated disease, the overall response rate was 41% (95% CI, 29%-53%) for those previously treated, which exceeded the 35% prespecified threshold for clinically relevant activity. The response rate was 68% (95% CI, 48%-84%) for those who had no prior treatment, which exceeded the 55% prespecified threshold for clinically relevant activity.

Activity was also seen in patients with brain metastases, with 7 of 13 patients with a MET exon 14 skipping mutation achieving an intracranial response 4 of which were complete responses.

Among patients with MET-amplified disease, the response rates were highest for previously treated and untreated patients with a gene copy number of at least 10 (29% and 40%, respectively), but neither were high enough to exceed the prespecified thresholds for clinically relevant activity.

The most common treatment-related adverse events were peripheral edema, nausea, vomiting, and increased blood creatinine level. One patient died from pneumonitis, which was suspected to be related to capmatinib.

The study authors concluded that capmatinib may be a new therapeutic option in patients with MET exon 14mutated advanced NSCLC.

Reference

Wolf J, Seto T, Han J, et al. Capmatinib in MET exon 14mutated or MET-amplified nonsmall-cell lung cancer. N Engl J Med. 2020;383:944-957. doi:10.1056/NEJMoa2002787

Here is the original post:
Capmatinib Shows Clinical Activity in MET Exon 14Mutated NSCLC - Cancer Therapy Advisor

Yale teams get multi-million-dollar awards to study biology of Parkinson’s – Yale News

Two Yale research teams will each receive approximately $9 million in grants from the Aligning Sciences Across Parkinsons (ASAP) initiative to study the underlying biology of Parkinsons disease.

The ASAP grants, to be distributed over three years, are part of a major international, multi-institutional effort to uncover the basic disease mechanisms that drive the progressive neurological disorder, which afflicts 7 to 10 million people worldwide. The initiative builds and leverages a network of leading investigators, which will ultimately serve to promote rapid access to data, enabling breakthroughs across scales that will accelerate benefits for patients.

A Yale team headed byPietro De Camilli, the John Klingenstein Professor of Neuroscience, professor of cell biology, and investigator for the Howard Hughes Medical Institute, will study how gene mutations linked to Parkinsons affect the function of brain cells during the course of the disease. De Camilli will team with scientists from Weill Cornell Medicine to study the impact of Parkinsons disease on the physiology and metabolism of synapses, with the goal of identifying new therapeutic targets.

A second Yale team led byDavid Hafler, the William S. and Lois Stiles Edgerly Professor of Neurology and professor of immunobiology, will investigate whether the progression of Parkinsons disease pathology in the brain is initiated by an autoimmune process triggered by the gut microbiome. The research, part of the Center for Neuroinflammation at Yale, will leverage long-standing collaborations with researchers from Massachusetts General Hospital and the Broad Institute to produce an unprecedented map of the neuro-immune-gut interactions, with the goal of identifying new treatments for the disease.

The awards to two Yale teams illustrate the universitys dedication to collaborative science and the growing role Yale neuroscientists are playing in elucidating fundamental mechanisms of the most intractable conditions afflicting the brain and central nervous system, said Nancy J. Brown, dean of the Yale School of Medicine. Without a more robust understanding of basic mechanisms we cannot make progress in the treatment of Parkinsonism, she added.

Other Yale members of the De Camilli team areKarin Reinisch, the David W. Wallace Professor of Cell Biology and of molecular biophysics and biochemistry;Shawn Ferguson, associate professor of cell biology and neuroscience; andKallol Gupta, assistant professor of cell biology.

Other Yale members of the Hafler team areLe Zhang, assistant professor of neurology;Sreeganga Chandra,associate professor of neurology and neuroscience;Rui Chang,assistant professor of neuroscience;Noah Palm,assistant professor of immunobiology;Brian KooandJesse Cedarbaum, members of the clinical Department of Neurology; andDavid van Dijk, assistant professor in the Department of Medicine and Genetics.

ASAP is a coordinated research initiative dedicated to fostering collaboration and resources to better understand the underlying causes of Parkinsons disease. The Michael J. Fox Foundation is ASAPs implementation partner and issued the grants.

View original post here:
Yale teams get multi-million-dollar awards to study biology of Parkinson's - Yale News

Oncologie Announces New Data and Analyses from Clinical Programs and Name Change to OncXerna Therapeutics – BioSpace

WALTHAM, Mass., Sept. 18, 2020 (GLOBE NEWSWIRE) -- Oncologie, Inc., a precision medicine company using an innovative RNA-based biomarker platform to predict patient responses for potentially first-in-class targeted oncology therapies, today announced new data and analyses from its lead clinical programs, bavituximab and navicixizumab. On the basis of these positive data, the company also announced its rebranding to OncXerna Therapeutics, Inc., a change that reinforces the companys focus on using its RNA-based approach to guide novel, targeted treatments to specific people with cancer.

With a deep understanding of the tumor microenvironment biology at the RNA-level through our novel biomarker panel, we aim to dramatically improve clinical outcomes by matching patients to therapies with a mechanism of action that targets that specific biology, said Laura Benjamin, Ph.D., President and Chief Executive Officer at OncXerna Therapeutics. Todays results demonstrate a clear ability of our first panel to distinguish responders versus non-responders in our bavituximab and navicixizumab programs, and we are excited to deploy this approach in the next prospectively-defined trials that could support registration.

Interim results from Phase 2 (ONCG100) trial of bavituximab and KEYTRUDA

Trial design and background:

The Phase 2 (ONCG100) trial is a multicenter, open-label, single-arm global trial designed to assess the safety, tolerability, and antitumor activity of the investigational agent bavituximab, a chimeric monoclonal antibody that targets phosphatidylserine, in combination with KEYTRUDA, Mercks anti-PD-1 therapy, in patients with advanced gastric and gastroesophageal cancer who have progressed on or after at least one prior standard therapy. Bavituximab previously demonstrated clinical activity in a post-hoc subset analysis in patients with non-small cell lung cancer (NSCLC) who were given a PD-1 inhibitor following bavituximab treatment, suggesting that a treatment combination of bavituximab and a PD-1 inhibitor could generate similar activity in a prospective clinical trial. In addition to measuring safety and antitumor activity in this trial, OncXerna is deploying its proprietary RNA biomarker platform (TME Panel-1) to identify patients based on their response to treatment and the dominant biology of their tumor microenvironment with the potential to dramatically improve outcomes in the next, prospectively designed trial.

Approximately 80 patients in the U.S., United Kingdom, South Korea and Taiwan are planned for enrollment in two separate groups of patients: Checkpoint inhibitor-nave and checkpoint inhibitor-relapsed. The trial is continuing to enroll both groups with planned updates from all patients during the first half of 2021.

Interim results:

Interim results provided today, from the first 36 patients enrolled and with a post-baseline scan in the checkpoint inhibitor-nave group, include the following:

Next steps:

These data are being presented at the European Society for Molecular Oncology (ESMO) Virtual Congress 2020 taking place September 19-21, 2020.

OncXerna plans to conduct additional clinical trials designed to prospectively enrich for TME Panel-1 biomarker positive patients, as well as to explore additional solid tumor types.

OncXerna biomarker analysis from Phase 1b trial evaluating navicixizumab in ovarian cancer

Previously announced data and background:

OncXernas navicixizumab is a bispecific antibody designed to inhibit both Delta-like ligand 4 (DLL4) in the Notch cancer stem cell pathway as well as vascular endothelial growth factor (VEGF). Interim data from a Phase 1b dose escalation and expansion trial of navicixizumab plus paclitaxel in 44 platinum-resistant ovarian cancer patients who had failed more than two prior therapies and/or received prior Avastin (bevacizumab) therapy were presented virtually at the 2020 Society of Gynecologic Oncology (SGO) Annual Meeting in May 2020. Treatment with navicixizumab and paclitaxel demonstrated an ORR of 43% in all patients, and 64% and 33% in bevacizumab-nave, and bevacizumab pre-treated patients, respectively. Treatment-related adverse events were manageable and included hypertension (58%), headache (29%), fatigue (26%) and pulmonary hypertension (18%).

Updated biomarker analyses and results:

Using its RNA-based biomarker TME Panel-1, OncXerna recently analyzed patient tissue samples obtained from 28 of the 44 patients from the Phase 1b trial. Results from this analysis revealed the following:

Next steps:

As a result of these analyses, OncXerna plans to conduct additional clinical trials designed to prospectively enrich for TME Panel-1 biomarker positive patients with ovarian cancer who are platinum-resistant and Avastin-experienced to support registration, as well as to explore additional solid tumor types.

About Bavituximab

Bavituximab is an investigational antibody that reverses immune suppression by inhibiting phosphatidylserine (PS) signaling and is currently in Phase 2 clinical trials to treat a specific subset of patients with advanced gastric cancer to improve their response to anti-PD-1 treatment. The mechanism of action of bavituximab is to block tumor immune suppression signaling from PS to multiple immune cell receptor families (e.g., TIMs and TAMs). The dominant biology targeted by bavituximab may be relevant for patients with many types of solid tumors whose immune systems are too suppressed to benefit from currently available immune oncology therapies. Our clinical trials currently combine bavituximab with KEYTRUDA to test the hypothesis that relieving immunosuppression can enhance responses to checkpoint inhibitors. Bavituximab is an investigational agent that has not been licensed or approved anywhere globally, and it has not been demonstrated to be safe or effective for any use, including for the treatment of advanced gastric cancer.

About Navicixizumab

Navicixizumab is an investigational anti-DLL4/VEGF bispecific antibody that has demonstrated antitumor activity in patients who have progressed on Avastin (bevacizumab) in a Phase 1a/b clinical trial. The U.S. Food and Drug Administration granted Fast Track designation to navicixizumab for the treatment of high-grade ovarian, primary peritoneal or fallopian tube cancer in patients who have received at least three prior therapies and/or prior treatment with Avastin. OncXerna is targeting patients whose dominant tumor biology is driven by angiogenesis with a focus beyond VEGF to include broader anti-angiogenic pathways. Navicixizumab is an investigational agent that has not been licensed or approved anywhere globally, and it has not been demonstrated to be safe or effective for any use, including for the treatment of advanced ovarian cancer.

About OncXerna Therapeutics

OncXerna is aiming to deliver next-generation precision medicine for a larger group of cancer patients by leveraging the companys deep understanding of how to prospectively identify patients based on the dominant, RNA-based biology of their tumor microenvironments. This allows OncXerna to pair those patients with OncXernas clinical-stage therapies and known mechanism of action that directly address these biologies, to dramatically improve patient outcomes. For more information on OncXerna, please visit oncxerna.com/

About OncXernas RNA-based Biomarker Platform

Existing precision medicines target only approximately 10% of cancersthose with gene mutations or oncogenic drivers for a small number of genes. Using its proprietary biomarker platform, OncXerna is leveraging the companys deep understanding of tumor biology at the RNA level to identify the dominant biology underlying a patients cancer. OncXernas first biomarker panel is specific to the tumor microenvironment (TME Panel-1). Initial results from TME Panel-1 reveal 4 different dominant biologies, demonstrating the presence of specific patient subgroups and their predictive value in responding to treatment. OncXerna is further optimizing the biomarker platforms tumor microenvironment panel through multiple research collaborations, including a collaboration with Moffitt Cancer Center.

KEYTRUDA is a registered trademark of Merck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc., Kenilworth, NJ, USA.

Investor and Media Contact:

Ashley R. RobinsonLifeSci Partners, LLCarr@lifesciadvisors.com

Read the original post:
Oncologie Announces New Data and Analyses from Clinical Programs and Name Change to OncXerna Therapeutics - BioSpace

LYNPARZA (olaparib) Improved Median Progression-Free Survival to Over Four and a Half Years Compared to 13.8 Months with Placebo for Patients with…

Sept. 18, 2020 10:45 UTC

KENILWORTH, N.J.--(BUSINESS WIRE)-- AstraZeneca and Merck (NYSE: MRK), known as MSD outside the United States and Canada, today announced positive five-year follow-up data from the Phase 3 SOLO-1 trial which demonstrated a long-term progression-free survival (PFS) benefit of LYNPARZA versus placebo as a first-line maintenance treatment in patients with newly diagnosed, advanced BRCA-mutated (BRCAm) ovarian cancer who were in complete or partial response to platinum-based chemotherapy.

Ovarian cancer is the eighth most common cause of cancer death in women worldwide and in 2018 there were nearly 300,000 new patients diagnosed and around 185,000 deaths globally. Approximately 22% of patients with ovarian cancer have a BRCA1/2 mutation.

Five-year follow-up data from the Phase 3 SOLO-1 trial showed LYNPARZA reduced the risk of disease progression or death by 67% (HR 0.33 [95% CI 0.250.43]), and improved median PFS to 56 months vs. 13.8 months for placebo. At five years, 48.3% of patients treated with LYNPARZA remained free from disease progression vs. 20.5% on placebo. The median duration of treatment with LYNPARZA was 24.6 months vs. 13.9 months with placebo. Median follow-up in the LYNPARZA arm was 4.8 years and 5 years for placebo.

The safety profile of LYNPARZA was consistent with previous observations in SOLO-1. The most common adverse reactions (ARs) 20% were nausea (77%), fatigue/asthenia (63%), vomiting (40%), anemia (39%) and diarrhea (34%). Grade 3 or greater ARs were reported in 40% of patients in the LYNPARZA arm with the most common being anemia (22%) and neutropenia (9%). ARs led to a dose interruption with LYNPARZA in 58% of patients and a dose reduction in 29% of patients. Twelve percent of patients on LYNPARZA discontinued treatment due to an AR.

Dr. Susana Banerjee, one of the investigators from the SOLO-1 trial and consultant medical oncologist at The Royal Marsden NHS Foundation Trust and reader at the Institute of Cancer Research, said, For patients with newly diagnosed BRCA-mutated advanced ovarian cancer, the benefit derived from two years of maintenance treatment with LYNPARZA continued long after treatment ended. At five years, almost half of these women had not progressed and were still living with stable disease. These results represent a significant step forward in the treatment of BRCA-mutated advanced ovarian cancer.

Dr. Jos Baselga, executive vice president, oncology R&D, AstraZeneca, said, Once a patients ovarian cancer recurs, it has historically been incurable. Even at an advanced stage, we have shown that maintenance treatment with LYNPARZA can help patients achieve sustained remission. Todays results further underline the critical importance of identifying a patients biomarker status at the time of diagnosis to be able to offer a maintenance treatment that may help delay disease progression for these patients.

Dr. Roy Baynes, senior vice president and head of global clinical development, chief medical officer, Merck Research Laboratories, said, This is the first trial of a PARP inhibitor to read out a five-year follow-up and showed LYNPARZA improved progression-free survival to over four and half years versus 13.8 months with placebo following response to first-line platinum-based chemotherapy. This latest data represents a major and significant milestone in a disease which has historically had such a poor prognosis.

Summary of efficacy results

Progression-Free Survival

(Primary Endpoint)

Recurrence-Free Survival*

(Post Hoc Analysis)

LYNPARZA

N=260

Placebo

N=131

LYNPARZA

N=189

Placebo

N=101

Events, n (%)

118 (45)

100 (76)

79 (42)

74 (73)

Median, m

56.0

13.8

NR

15.3

HR (95% CI)

0.33 (0.250.43)

0.37 (0.270.52)

Patients progression or recurrence free at timepoint, % (Kaplan-Meier estimates)

These analyses are descriptive only; the SOLO-1 trial was not powered to assess a

statistical difference between treatment groups at these time points

1y

87.7 (N=212)

51.4 (N=65)

91.0 (N=159)

58.0 (N=56)

2y

73.6 (N=173)

34.6 (N=41)

77.2 (N=132)

39.0 (N=35)

3y

60.1 (N=129)

26.9 (N=30)

64.0 (N=99)

28.9 (N=25)

4y

52.3 (N=101)

21.5 (N=23)

55.2 (N=75)

23.0 (N=19)

5y

48.3 (N=58)

20.5 (N=16)

51.9 (N=42)

21.8 (N=12)

*Defined post hoc as time from randomization to disease recurrence or death. Patients had complete response at baseline based on electronic case report form data. CI, confidence interval; HR, hazard ratio; NR, not reached

The results were presented on Friday, Sept. 18, 2020, at the European Society for Medical Oncology (ESMO) Virtual Congress 2020 (Abstract #811MO).

The Phase 3 SOLO-1 trial met the primary endpoint of PFS in June 2018, which formed the basis of approvals in the U.S., the EU, Japan, China and several other countries.

About SOLO-1

SOLO-1 was a Phase 3, randomized, double-blinded, placebo-controlled, multi-center trial to evaluate the efficacy and safety of LYNPARZA tablets (300 mg twice daily) as a maintenance monotherapy compared with placebo in newly diagnosed patients with BRCAm advanced ovarian cancer following response to first-line platinum-based chemotherapy. The trial randomized 391 patients with a deleterious or suspected deleterious germline or somatic BRCA1 or BRCA2 mutation who were in clinical complete or partial response following platinum-based chemotherapy.

Patients were randomized (2:1) to receive LYNPARZA or placebo for up to two years or until disease progression. Patients who had a partial response at two years were permitted to stay on therapy at the investigators discretion. The primary endpoint was investigator-assessed PFS and key secondary endpoints included time to second disease progression or death, time to first subsequent treatment and overall survival. The primary analysis results were presented at the 2018 ESMO Congress and published in The New England Journal of Medicine.

IMPORTANT SAFETY INFORMATION

CONTRAINDICATIONS

There are no contraindications for LYNPARZA.

WARNINGS AND PRECAUTIONS

Myelodysplastic Syndrome/Acute Myeloid Leukemia (MDS/AML): Occurred in <1.5% of patients exposed to LYNPARZA monotherapy, and the majority of events had a fatal outcome. The duration of therapy in patients who developed secondary MDS/AML varied from <6 months to >2 years. All of these patients had previous chemotherapy with platinum agents and/or other DNA-damaging agents, including radiotherapy, and some also had a history of more than one primary malignancy or of bone marrow dysplasia.

Do not start LYNPARZA until patients have recovered from hematological toxicity caused by previous chemotherapy (Grade 1). Monitor complete blood count for cytopenia at baseline and monthly thereafter for clinically significant changes during treatment. For prolonged hematological toxicities, interrupt LYNPARZA and monitor blood count weekly until recovery.

If the levels have not recovered to Grade 1 or less after 4 weeks, refer the patient to a hematologist for further investigations, including bone marrow analysis and blood sample for cytogenetics. Discontinue LYNPARZA if MDS/AML is confirmed.

Pneumonitis: Occurred in <1% of patients exposed to LYNPARZA, and some cases were fatal. If patients present with new or worsening respiratory symptoms such as dyspnea, cough, and fever, or a radiological abnormality occurs, interrupt LYNPARZA treatment and initiate prompt investigation. Discontinue LYNPARZA if pneumonitis is confirmed and treat patient appropriately.

Embryo-Fetal Toxicity: Based on its mechanism of action and findings in animals, LYNPARZA can cause fetal harm. A pregnancy test is recommended for females of reproductive potential prior to initiating treatment.

Females

Advise females of reproductive potential of the potential risk to a fetus and to use effective contraception during treatment and for 6 months following the last dose.

Males

Advise male patients with female partners of reproductive potential or who are pregnant to use effective contraception during treatment and for 3 months following the last dose of LYNPARZA and to not donate sperm during this time.

Venous Thromboembolic Events: Including pulmonary embolism, occurred in 7% of patients with metastatic castration-resistant prostate cancer who received LYNPARZA plus androgen deprivation therapy (ADT) compared to 3.1% of patients receiving enzalutamide or abiraterone plus ADT in the PROfound study. Patients receiving LYNPARZA and ADT had a 6% incidence of pulmonary embolism compared to 0.8% of patients treated with ADT plus either enzalutamide or abiraterone. Monitor patients for signs and symptoms of venous thrombosis and pulmonary embolism, and treat as medically appropriate, which may include long-term anticoagulation as clinically indicated.

ADVERSE REACTIONSFirst-Line Maintenance BRCAm Advanced Ovarian Cancer

Most common adverse reactions (Grades 1-4) in 10% of patients in clinical trials of LYNPARZA in the first-line maintenance setting for SOLO-1 were: nausea (77%), fatigue (67%), abdominal pain (45%), vomiting (40%), anemia (38%), diarrhea (37%), constipation (28%), upper respiratory tract infection/influenza/ nasopharyngitis/bronchitis (28%), dysgeusia (26%), decreased appetite (20%), dizziness (20%), neutropenia (17%), dyspepsia (17%), dyspnea (15%), leukopenia (13%), UTI (13%), thrombocytopenia (11%), and stomatitis (11%).

Most common laboratory abnormalities (Grades 1-4) in 25% of patients in clinical trials of LYNPARZA in the first-line maintenance setting for SOLO-1 were: decrease in hemoglobin (87%), increase in mean corpuscular volume (87%), decrease in leukocytes (70%), decrease in lymphocytes (67%), decrease in absolute neutrophil count (51%), decrease in platelets (35%), and increase in serum creatinine (34%).

ADVERSE REACTIONSFirst-Line Maintenance Advanced Ovarian Cancer in Combination with Bevacizumab

Most common adverse reactions (Grades 1-4) in 10% of patients treated with LYNPARZA/bevacizumab compared to a 5% frequency for placebo/bevacizumab in the first-line maintenance setting for PAOLA-1 were: nausea (53%), fatigue (including asthenia) (53%), anemia (41%), lymphopenia (24%), vomiting (22%) and leukopenia (18%). In addition, the most common adverse reactions (10%) for patients receiving LYNPARZA/bevacizumab irrespective of the frequency compared with the placebo/bevacizumab arm were: diarrhea (18%), neutropenia (18%), urinary tract infection (15%), and headache (14%).

In addition, venous thromboembolic events occurred more commonly in patients receiving LYNPARZA/bevacizumab (5%) than in those receiving placebo/bevacizumab (1.9%).

Most common laboratory abnormalities (Grades 1-4) in 25% of patients for LYNPARZA in combination with bevacizumab in the first-line maintenance setting for PAOLA-1 were: decrease in hemoglobin (79%), decrease in lymphocytes (63%), increase in serum creatinine (61%), decrease in leukocytes (59%), decrease in absolute neutrophil count (35%), and decrease in platelets (35%).

ADVERSE REACTIONSMaintenance Recurrent Ovarian Cancer

Most common adverse reactions (Grades 1-4) in 20% of patients in clinical trials of LYNPARZA in the maintenance setting for SOLO-2 were: nausea (76%), fatigue (including asthenia) (66%), anemia (44%), vomiting (37%), nasopharyngitis/upper respiratory tract infection (URI)/influenza (36%), diarrhea (33%), arthralgia/myalgia (30%), dysgeusia (27%), headache (26%), decreased appetite (22%), and stomatitis (20%).

Study 19: nausea (71%), fatigue (including asthenia) (63%), vomiting (35%), diarrhea (28%), anemia (23%), respiratory tract infection (22%), constipation (22%), headache (21%), decreased appetite (21%), and dyspepsia (20%).

Most common laboratory abnormalities (Grades 1-4) in 25% of patients in clinical trials of LYNPARZA in the maintenance setting (SOLO-2/Study 19) were: increase in mean corpuscular volume (89%/82%), decrease in hemoglobin (83%/82%), decrease in leukocytes (69%/58%), decrease in lymphocytes (67%/52%), decrease in absolute neutrophil count (51%/47%), increase in serum creatinine (44%/45%), and decrease in platelets (42%/36%).

ADVERSE REACTIONSAdvanced gBRCAm Ovarian Cancer

Most common adverse reactions (Grades 1-4) in 20% of patients in clinical trials of

LYNPARZA for advanced gBRCAm ovarian cancer after 3 or more lines of chemotherapy (pooled from 6 studies) were: fatigue/asthenia (66%), nausea (64%), vomiting (43%), anemia (34%), diarrhea (31%), nasopharyngitis/upper respiratory tract infection (URI) (26%), dyspepsia (25%), myalgia (22%), decreased appetite (22%), and arthralgia/musculoskeletal pain (21%).

Most common laboratory abnormalities (Grades 1-4) in 25% of patients in clinical trials of LYNPARZA for advanced gBRCAm ovarian cancer (pooled from 6 studies) were: decrease in hemoglobin (90%), mean corpuscular volume elevation (57%), decrease in lymphocytes (56%), increase in serum creatinine (30%), decrease in platelets (30%), and decrease in absolute neutrophil count (25%).

ADVERSE REACTIONSgBRCAm, HER2-negative Metastatic Breast Cancer

Most common adverse reactions (Grades 1-4) in 20% of patients in OlympiAD were: nausea (58%), anemia (40%), fatigue (including asthenia) (37%), vomiting (30%), neutropenia (27%), respiratory tract infection (27%), leukopenia (25%), diarrhea (21%), and headache (20%).

Most common laboratory abnormalities (Grades 1-4) in >25% of patients in OlympiAD were: decrease in hemoglobin (82%), decrease in lymphocytes (73%), decrease in leukocytes (71%), increase in mean corpuscular volume (71%), decrease in absolute neutrophil count (46%), and decrease in platelets (33%).

Go here to see the original:
LYNPARZA (olaparib) Improved Median Progression-Free Survival to Over Four and a Half Years Compared to 13.8 Months with Placebo for Patients with...

3D curvature-instructed endothelial flow response and tissue vascularization – Science Advances

Fabrication and endothelialization of spiral tubes in PDMS and collagen gels

We exploited subtractive molding techniques to fabricate spiral tubes in both polydimethylsiloxane (PDMS) and collagen hydrogels and tested the fabrication limit and fidelity. In PDMS, stainless steel springs of various dimensions were molded in liquid-phase PDMS (10:1, base:curing agent) and manually removed after cross-linking. Robust perfusable spiral tubes with constant curvature were generated in PDMS with a diameter larger than 200 m and a pitch greater than 1 mm per turn. The fabrication of smaller spiral tubes in PDMS is less consistent because of the distortion of the channel structure during spring removal. In collagen hydrogels (6 to 7.5 mg/ml), an automatic two-axis motion system was designed to retract the spring from the hydrogel after thermal gelation. Automatic retraction was critical to minimize distortion of the spiral pattern and maximize continuity of the luminal geometry in three dimensions in soft matrices (see Materials and Methods) (Fig. 1A). Spiral tubes of a wide range of wire diameter (dw = 120 to 400 m), spiral diameter (ds = 1 to 3 mm), and pitch (p 400 m) were formed in collagen hydrogels, corresponding to curvature in the range of 0.43 to 1.05 mm1 and torsion in the range of 0.32 to 0.72 mm1 (fig. S1A). Fluorescent beads were perfused to visualize the 3D structure of the spiral lumen [Fig. 1B (a); fig. S1, A and B; and movie S1], where loops of the spiral tubes were periodically spaced with distinct boundaries. Using off-the-shelf springs, we were able to achieve spacing between loops ( = p dw) as small as 210 m. We further modified the spiral mold by adding a cylinder in the center of the spring to generate a second independently perfusable lumen in the hydrogel structure [Fig. 1B (b)]. We fabricated constructs with a central tube concentrically wrapped with a spiral tube and separated by a wall as thin as 200 m.

(A) Schematic of spiral vessel fabrication strategy. Top: A hydrogel is cross-linked around an off-the-shelf spring (a), the pattern is retracted from the gel via a two-axis motion system (b), and vessels were seeded with cells by perfusion (c). Bottom: An independent rod was introduced at the center of the spring to form an additional lumen for independent access and cell seeding. (B) (a) Maximum intensity projection (MIP) of a confocal z-stack of a spiral vessel in collagen perfused with fluorescent beads. (b) Optical section of a collagen spiral vessel (magenta) with an independently perfused center channel (green). Scale bars, 500 m. (C to E) MIP of side (C) and top (D) views of an endothelialized spiral vessel in PDMS and top view of endothelialized collagen vessel (E). Scale bars, 750, 600, and 150 m. (F) Integrated fabrication of spiral vessel (z directional flow) and planar microvessel (x and y directional flow) showing MIP of side and top views with magnified views of regions near (a) and distant from the connection of spiral to planar microvessels (b and c). Magenta, CD31; green, von Willebrand factor; blue, nuclei. Scale bars, 200 m and 50 m (inset). (G) Engineered vascularized tumor model with ECs from the spiral vessel sprouting toward avascular tumor cells embedded in the center lumen of the spiral. Green, CD31; red, KG1a cancer cells; blue, nuclei. Scale bars, 200 m (left) and 100 m (right). (H) Vascularized cardiac chamber model. Green, CD31; red, cTnT; blue, nuclei. Scale bars, 500 m.

Next, we perfused human umbilical vein ECs (HUVECs) into the spiral tubes in either PDMS or collagen to allow cell attachment followed by culture under flow. Both materials supported the growth of a robust endothelium under steady flow for at least 1 week (Q = 1 l/min; Fig. 1, C to E). PDMS spiral vessels with a lumen diameter of less than 200 m often had sparse coverage of ECs on the vessel surface after seeding and were not used in experimental conditions. Collagen spiral vessels better supported endothelialization, and HUVECs were seeded and cultured under similar flow conditions for spiral vessels as small as 180 m with high reproducibility (fig. S1C). ECs in PDMS vessels (lumen diameter > 200 m) and all sized collagen vessels had robust junctions at cell-cell contacts and localized expression of CD31 to the plasma membrane (Fig. 1, C to E). Together, we successfully generated spiral microvessels with constant curvature and torsion at high fidelity and reproducibility and with robust endothelialization and perfusion.

The fabrication process for spiral vessels has the flexibility to integrate with existing vascularization approaches to further enhance tissue perfusion. By incorporating ECs into the bulk matrix, the endothelium in spiral tubes was readily anastomosed with self-assembled vessel networks and increased vascular density (fig. S1D). When combined with lithography and injection molding techniques (31), we successfully connected a spiral vessel with a microfabricated rectilinear vessel so that the spiral outflow was connected to the perfusion of microvessels in an orthogonal direction to the spiral. This integration allows the rotation of the spiral flow direction into another plane and mimics the architecture of the spiral artery to vascular bed connection found in vivo (Fig. 1F). We observed a continuous endothelium in the spiral microvessel connection [Fig. 1F (a)]. ECs in the planar microvessels near the spiral vessel outflow showed greater alignment with the direction of flow, likely due to higher flow stresses [Fig. 1F (a); average angle, 13.5 10.2] compared to cells in regions distant from the spiral microvessel interface [Fig. 1F (b and c); average angle, 39.3 23.7 and 58.13 29.25, respectively]. These findings illustrate the potential of spiral vessels as a new strategy for rapidly generating long and high surface area vascular structures that may enhance tissue vascularization.

Using the concentric spiral platform in collagen gel, we further demonstrated the potential of spiral vessels in supporting 3D tissue function. By dispensing tumor cells (KG1a, a leukemia cell line; Materials and Methods) in a collagen gel (6 mg/ml) into the spatially defined center cylinder (1.3 mm diameter), we formed an artificial tumor surrounded by spiral vessels and monitored the sprouting of vessels from the spiral. This cell-remodelable system mimics the physiological origins of some tumors, where malignancies begin as an avascular cellular mass surrounded by host vasculature that it must recruit for expansion (32). When cultured under flow (Q = 1 l/min) in normal growth medium, spiral vessels (dw = 400 m, ds = 3.0 mm, and p = 1 mm) maintained patency throughout 7 days of culture and sprouted consistently by day 7, but not at day 3 (N = 4 for each time point) (Fig. 1G). These sprouts extended exclusively toward the tumor, with sprouts reaching as far as 220 m from the vessel wall by day 7. No sprouts were observed when there were no tumor cells in the center.

We also created a thick cardiac chamber supported by a spiral vessel using the same concentric model (1.3-mm-diameter by 6-mm-long chamber surrounded by spiral vessel). GCaMP3-transduced human embryonic stem cellderived cardiomyocytes (hESC-CMs) and stromal cells (HS27a) were added into the bulk collagen matrix (33) and ECs (HUVECs) into both the bulk matrix and the spiral lumen, while the center of the tissue was kept open (Fig. 1H). By day 12 of culture, organized calcium waves were observed and appeared to propagate in three dimensions along the spiral vessel wall (movie S2). The conduction velocity in engineered cardiac tissues was 2.7 0.97 cm/s, as determined by analysis of the GCaMP3 signal (fig. S2). These proof-of-concept examples show that the spiral vessel platform can be used to support 3D vascularization and perfusion in large tissues, to study the vascular-tissue interaction in a spatially and temporally controlled manner, and to model complex tissue functions.

We next examined the flow characteristics in these spiral microvessels and compared them with straight vessels of the same caliber. We visualized the flow characteristics by perfusing fluorescent bead solutions in two parallel streams through straight and spiral PDMS vessels of the same diameter and length (dvessel = 400 m, dspiral = 3 mm, pspiral = 1 mm, spiral = 0.46 mm1, spiral = 0.31 mm1, and L = 6.5 cm) at three steady flow conditions (Q = 1, 50, and 100 l/min, corresponding to Re = 0.01, 0.76, and 1.52, respectively). The 3D flow images were taken under confocal fluorescence microscopy at set distances (Lv = 5, 30, and 55 mm in straight vessels, or loops 3/4, 3 3/4, and 6 3/4 in spiral vessels) from the vessel inlet. Straight tubes displayed a classical parallel flow profile where the two streams of beads traveled to the outlet and maintained their position over the whole vessel length at both flow rates (Fig. 2, A and C). In spiral tubes, the two bead streams remained distinct and parallel at low flow (Q = 1 l/min) but rotated over the vessel length without obvious mixing in the bulk [Fig. 2B (a to c)]. The orientation of the two parallel streams inverted after approximately four loops from the inlet [Fig. 2B (b)] and completed a full rotation at approximately loop 7 [Fig. 2B (c)]. At a higher flow rate (Q = 50 l/min) in the same spiral geometry (De = 2.77), the two bead streams developed obvious bulk mixing with the leading edge of flow rotating 270 after three loops [Fig. 2B (e)] and completed another full rotation by loop 7 [Fig. 2B (f)]. At even higher flow (Q = 100 l/min), a stronger mixing effect was observed in the same spiral geometry [Fig. 2B (g to i)], whereas the two streams remained parallel and unmixed in straight vessels under the same flow conditions.

(A and B) Confocal cross sections of perfusion of two parallel streams of red and blue beads into a straight PDMS vessel (A) at a flow rate of Q = 50 l/min and a spiral PDMS vessel (B) at three flow rates (Q = 1, 50, and 100 l/min) at three distances from the vessel inlet (Lv,a 5 mm, Lv,b 30 mm, and Lv,c 55 mm), corresponding to the 3/4, 3 3/4, and 6 3/4 spiral loops (LL = linear length, Lv = vessel length, dv = vessel diameter, p = pitch). (C and D) Computational fluid dynamics plots of straight (C) and spiral (D) vessels at Q = 50 l/min for (a) streamlines (color expressed with primary velocity magnitude), (b) primary velocity magnitude, (c) secondary flow velocity orthogonal to cross-sectional plane, and (d) shear rate at the cross-sectional views.

Using numerical simulation with COMSOL, we confirmed these flow characteristics: (i) Idealized parallel streamlines were present in fully developed flow in straight vessels [Fig. 2C (a)]; (ii) parallel streamlines in spiral vessels slightly rotate along circumferential direction at low flow (Q = 1 l/min; fig. S3A); and (iii) streamline rotation was enhanced in spiral vessels and developed twists at higher flow [Q = 50 l/min; Fig. 2D (a)] and had clear twists at Q = 100 l/min (fig. S3B). The spiral geometry did not induce a significant change in the primary flow compared to straight vessels but did lead to the emergence of secondary flows with a peak magnitude of around 1% of the primary flow velocity [Q = 50 l/min; Fig. 2, C (b and c) and D (b and c)]. This also led to the development of a shear stress gradient in 3D space and a change in the wall shear stress (WSS), with a maximum (10% increase over the straight tube) on the surface of the inner curvature and minimum on the outer bend, unlike in a straight tube where the WSS was constant across the lumen cross section with zero gradients [Fig. 2, C (d) and D (d)]. These data demonstrated that spiral vessels induced bulk flow mixing and heterogeneous hemodynamic forces on the endothelium lining the wall due to 3D curvature and torsion.

To understand how the distinct hemodynamic features of flow in spiral vessels affected ECs, we cultured cells in both geometries under flow. In straight and spiral vessels, ECs formed robust junctions and a stable endothelium in low (Q = 1 l/min and WSS = 0.1 dyne/cm2 in straight vessels) and high (Q = 50 l/min and WSS = 4.6 dynes/cm2 in straight vessels) flow conditions. The increased flow appeared to change the EC morphology and enhance EC alignment in the direction of flow (Fig. 3A). Under low flow conditions (Q = 1 l/min; Fig. 3B), fewer Ki67+ proliferating cells were observed in spiral vessels than in straight vessels. When exposed to higher flow, however, more proliferating cells were observed in the spiral geometry than the straight geometry, suggesting distinct roles for geometry and flow on the ECs. Previous literature has highlighted that very low laminar flows activate ECs, whereas high laminar flow enhances EC quiescence (11). Our data were consistent with this in straight vessels with significantly reduced cell proliferation at higher flow. In spiral vessels, however, the flow rotation in low flow may alter transport and promote quiescence at low flow. Given that the magnitude of flow forces is very low in the low flow conditions, it is also likely that differences in substrate curvature between straight and spiral geometries contribute to these observed differences (34).

(A) MIP of EC cultured under flow (Q = 50 l/min) for 24 hours. Blue, nuclei; green, CD31; red, Ki67. Scale bar, 50 m. (B) Quantification of the percentage of Ki67-positive nuclei by counting 100+ cells per vessel in N = 3 vessels at two flow conditions (Q = 1 and 50 l/min). Error bars represent 95% confidence interval of the mean. *P < 0.05 using a one-way analysis of variance (ANOVA) with Tukeys pairwise comparisons. (C) PCA of RNA-seq data from cells cultured at static and at two flow conditions in two vessel geometries (N = 3). (D) Venn diagram showing the overlap of genes significantly changed by increasing flow in straight and spiral geometries. (E) Heatmap of log counts per million (CPM) values of known flow-responsive genes. All genes are present in the overlapping region of (D) (green). (F) Heatmaps of the CPM values of significantly regulated transcripts belonging to the nonoverlapping regions of (D). Three hundred fifty-five genes uniquely regulated in straight high versus low (top, yellow) and 1261 genes uniquely regulated in spiral high versus low (bottom, blue). (G) Heatmaps of the CPM values of selected growth factors, transporters, and transcription factors. (H) IPA functional pathways identified by comparing spiral to straight vessels under high flow.

We next examined the transcriptional changes in ECs in these conditions via RNA sequencing (RNA-seq) for ECs cultured under both flow conditions in straight and spiral vessels and under static conditions. Principal components analysis (PCA) of gene expression data showed clustering of individual groups, with the largest variance between static and all flow conditions (Fig. 3C). Activation of classical flow-dependent genes was confirmed in all flow conditions compared to static culture (Fig. 3, D and E). Among these genes, KLF2 and KLF4 appeared to only change with the onset of flow but were not sensitive to a further increase in flow, whereas SMAD6, SMAD7, and NOS3 increased further at higher flow conditions. Among the genes differentially expressed in straight vessels due to the increase of flow, 52% (533 of 1012) overlap with genes differentially expressed in the onset of flow (static versus low flow condition) (fig. S4, A and B). The genes unique to the increase of flow include up-regulation of many genes previously reported to regulate vascular development and flow sensing (35), such as Notch ligands JAG1 and JAG2; Notch target HEY2 and other transcription factors such as SNAI2; transmembrane proteins IL21R and EFNB2; transporter GJA5; peptidases MMP10, MMP1, and MT1F; growth factors and cytokines NOG, DKK2, WNT4, CXCL12, and TGFB1; and other molecules such as VCAN and CYP1B1 (fig. S4C). Gene Ontology (GO)enriched terms for this group of genes showed up-regulation of cellular response to growth factors, vascular development, transmembrane receptor protein tyrosine kinase signaling pathway, blood vessel morphogenesis, cell migration and motility, and others (fig. S4D).

Approximately 66% (722 of 1136) of differentially expressed genes in straight vessels overlap with those in spiral vessels in response to increased flow (Fig. 3D). Almost all overlapping genes are changed in the same direction (99%), suggesting a conserved response to flow in both geometries (fig. S5A). MARC2, PTX3, and STX11 did not follow this trend and were up-regulated in spiral vessels with increased flow but down-regulated in straight vessels. PTX3 has been reported as a biomarker for endothelial dysfunction in preeclampsia, which is a disease caused by spiral artery dysfunction (36). Many genes down-regulated in straight vessels by the increase of flow did not show changes in spiral vessels, such as growth factors CTGF, FGF2, NRG1, and FGF16; transmembrane proteins CAV1, UNC5A, KIT, and SMAD4A; transcription regulators EGR1/2/3, MAF, MYRF, and MZF1; transporters such as LDLR; and cytokines TNFSF18, IL12A, CCL2, CCL16, and CCL28 (fig. S5B). This suggests that the EC response to flow in spiral vessels is a combination of both canonical flow pathways and a distinct response involving a wide range of other transcripts.

Increased flow also led to an additional 1294 genes significantly changed in spiral vessels that were not in straight ones (Fig. 3F). High flow in spiral vessels appeared to activate growth factors such as DKK1, ESM1, BMP2, PDGFA, OSGIN2, and VEGFC; many solute carrier (SLC) and adenosine triphosphate (ATP)binding cassette (ABC) superfamily transporters; transcriptional regulators such as GLI2; cytokine CXCL1; peptidases TLL1, ADAMTS1, ADAMTS9, and TASP1; and kinases PODXL, EPHA5, HK2, PRKCA, CCT2, and MAP2K1 (Fig. 3G and fig. S6A). In addition, high flow in spiral vessels repressed growth factors such as MST, NRG2, GDF3, GAS6, and IGF2; transmembrane receptors CHRNA1, SELP, LRP1, ITGB3, and ROBO3; transporters including MAL2, ATP2A3, RBP1, and APOL1 and several members of SLC and ABC superfamilies; transcriptional regulators such as NOTCH3, CITED4, CAND2, FOXO4, DACH1, and EBF3; cytokines DKK3, CSF1, and FLT3LG; GPCR (G proteincoupled receptor) group SIPR4, OPRL1, and HTR2B; and kinases PDGFRB, CKB, and SBK1 (Fig. 3F and fig. S6A). GO term analysis showed the up-regulation of primarily ribosome biogenesis, which would be critical for cellular growth and proliferation (fig. S6B). These expression profiles show that spiral vessels share a common set of flow-responsive elements with straight vessels but have an additional response that appeared to promote vascular growth.

PCA analysis showed that the separation of straight and spiral geometries was enhanced under higher flow conditions (Fig. 3E). Under low flow conditions (Re << 1; inertia effect is negligible), ECs in the two geometries were largely similar, with only a handful of significantly regulated transcripts (fig. S7A). These included CYTL1, which is known to up-regulate proangiogenic function, but not proinflammatory pathways (37). HES2, a downstream Notch pathway gene, STK32B (serine/threonine kinase 32B), and CCND1, a cell cycle regulation gene, were also up-regulated in low flow spiral vessels. The up-regulation of these genes was further enhanced in high flow conditions. In addition, many genes that regulate vascular development were up-regulated when comparing spiral to straight vessels at high flow, for example, growth factors HGF, DKK1, ESM1, PGF, PDGFA, GDF6, PDGFB, CTGF, VEGFC, BMP2, and PDGFC; peptidases ADAMTS1, ADAMTS9, MME, and CTSS; kinases EPHA5, MPP4, PODXL, SPRY2, CDK7, and MAP2K1; transmembrane receptors KIT, SELE, ULBP2, PLXNA2, and LRP8; transcriptional regulators GLI2 (a hedgehog pathway mediator), ATF3 (required for endothelial regeneration) (38), and FOSL1 (required for vascular formation) (39); and many SLC and ATP family transporters (Fig. 3G). Ingenuity Pathway Analysis (IPA) showed that ECs in spiral vessels have activated upstream regulators including prosurvival factors HGF, PGF, EGF, VEGF, and HIF-1a. Up-regulated functional pathways included vascular development, angiogenesis, vasculogenesis, cell invasion, and cell survival, whereas cell death and necrosis were decreased compared to the straight vessel in high flow conditions (Fig. 3H and fig. S7B). Spiral vessels also showed the activation of antiapoptotic and proliferative pathways marked by cell cycle and mitotic genes. PDGF (platelet-derived growth factor) family members were relatively more abundant, as were molecules associated with IL-8 (interleukin-8) and HGF (hepatocyte growth factor) signaling (fig. S7B).

Together, the bulk RNA-seq showed that spiral vessels maintain a normal flow response to a certain extent, but curvature and torsion modified the response by up-regulating markers for transporters, cycling, and survival and down-regulating markers of cell death. These data suggest that flow in spiral vessels promoted vascular growth or development rather than inducing a common inflammatory response to disturbed flow.

We hypothesized that ECs exposed to flow within spiral vessels experienced a spatial variation in hemodynamic forces not present in straight vessels that would result in a heterogeneous transcriptional response to flow. To understand this heterogeneity at the single-cell level, we sequenced the transcriptomes of more than 2000 individual ECs pooled from three to four devices of each geometry cultured at high flow (Q = 50 l/min). Dimensionality reduction by Uniform Manifold Approximation and Projection (UMAP) and cluster analysis was performed using Monocle (4042). Projection in the top two UMAP dimensions shows overlapping contributions of ECs from spiral and straight vessels that form mostly contiguous clusters with nearly uniform expression of pan-endothelial markers such as CDH5 (VE-cadherin) (Fig. 4, A and B). Expression of classical flow-dependent genes, including KLF4 and NOS3, is distributed throughout the major clusters of ECs in this projection (Fig. 4C). We identified variation in gene expression across the first UMAP dimension driven largely by cell cycle genes that have been shown to be regulated, in part, by flow. Specifically, a large cluster of cells to the right in UMAP space (cluster 3) express genes such as MKI67, consistent with active cell cycle status, whereas cells clustered to the opposite pole (cluster 1) express genes implicated in cell cycle arrest and arterial phenotype shown to be regulated by the Notch pathway downstream of laminar shear stress (including CDKN1C, EFNB2, HEY1, GJA4, and IL33; Fig. 4C) (4345).

(A) UMAP plots of spiral high flow and straight high flow cells, computationally derived clusters (B), and the distribution of endothelial and cell cycling genes across cells (C). (D) UMAP plots of the first and third UMAP dimensions, the corresponding location of clusters in this dimensional space (E) with examples of cluster specific genes (F), as well as a selection of genes identified as significantly differentially expressed (G).

To evaluate heterogeneity in the transcriptional response of ECs resulting from vessel geometry, we next identified differentially expressed genes on the basis of single-cell RNA-seq (scRNA-seq) data of EC from straight versus spiral vessels. Examination of the third UMAP dimension revealed separation in transcriptional space between EC from straight versus spiral vessels, with many of the identified differentially expressed genes polarized in this dimension (Fig. 4, D to F). Among the genes up-regulated in EC from spiral vessels are many that were also identified as differentially expressed in bulk RNA-seq analysis, including ATF3, SPRY2, IL8, JUN, AKAP12, ANGPTL4, FOSL1, ADAMTS1, and ADAMTS9 (Fig. 4G and fig. S8A). Most of these genes are expressed in a common pattern, with increased expression in cells localized in UMAP space to the lower (spiral) portion of cluster 2. This suggests a distinct transcriptional program among the primarily spiral ECs in this region that may correspond with their transcriptional response to specific hemodynamic conditions unique to spiral vessels under high flow. In further support of this hypothesis, analysis of the scRNA-seq data also identified differentially expressed genes not detected in bulk RNA-seq, including DCN, SLC6A9, GEM, NRG1, RSPO3, BAMBI, TGFBI, and PRRX2, that were highly specific to EC from spiral vessels localized in cluster 2 (Fig. 4G and fig. S8B). These data suggest that flow in spiral vessels induced a population of ECs with unique gene expression profiles that are not present in straight vessels, with potential roles in processes such as angiogenesis, vascular growth, and inflammatory and stress responses.

Read this article:
3D curvature-instructed endothelial flow response and tissue vascularization - Science Advances

CRISPR Market to Witness Exponential Growth by 2020-2027 | Leading Players Thermo Fisher Scientific, Editas Medicine, Caribou Biosciences, CRISPR…

Fort Collins, Colorado The report on the CRISPR Market provides an in-depth assessment of the CRISPR market including technological advancements, market drivers, challenges, current and emerging trends, opportunities, threats, risks, strategic developments, product advancements, and other key features. The report covers market size estimation, share, growth rate, global position, and regional analysis of the market. The report also covers forecast estimations for investments in the CRISPR industry from 2020 to 2027.

The report is furnished with the latest market dynamics and economic scenario in regards to the COVID-19 pandemic. The pandemic has brought about drastic changes in the economy of the world and has affected several key segments and growth opportunities. The report provides an in-depth impact analysis of the pandemic on the market to better understand the latest changes in the market and gain a futuristic outlook on a post-COVID-19 scenario.

Global CRISPR Market Size Study by Application(Genome Editing, Genetic Engineering, Gene Library, CRISPR Plasmid, Human Stem cells, Genetically Modified Organism, Cell Line Engineering), by End-User (Biotechnology Companies, Pharmaceutical Companies, Academic Institutes, Research & Development Institutes) and Regional Forecast 2017-2025.

Get a sample of the report @ https://reportsglobe.com/download-sample/?rid=5977

The report provides an in-depth analysis of the key developments and innovations of the market, such as research and development advancements, product launches, mergers & acquisitions, joint ventures, partnerships, government deals, and collaborations. The report provides a comprehensive overview of the regional growth of each market player.

Additionally, the report provides details about the revenue estimation, financial standings, capacity, import/export, supply and demand ratio, production and consumption trends, CAGR, market share, market growth dynamics, and market segmentation analysis.

The report covers extensive analysis of the key market players in the market, along with their business overview, expansion plans, and strategies. The key players studied in the report include:

Furthermore, the report utilizes advanced analytical tools such as SWOT analysis and Porters Five Forces Analysis to analyze key industry players and their market scope. The report also provides feasibility analysis and investment return analysis. It also provides strategic recommendations to formulate investment strategies and provides insights for new entrants.

Request a discount on the report @ https://reportsglobe.com/ask-for-discount/?rid=5977

The report is designed with an aim to assist the reader in taking beneficial data and making fruitful decisions to accelerate their businesses. The report provides an examination of the economic scenario, along with benefits, limitations, supply, production, demands, and development rate of the market.

By Applications:

By End User:

Request customization of the report @https://reportsglobe.com/need-customization/?rid=5977

Regional Analysis of the Market:

For a better understanding of the global CRISPR market dynamics, a regional analysis of the market across key geographical areas is offered in the report. The market is spread acrossNorth America, Europe, Latin America, Asia-Pacific, and Middle East & Africa.Each region is analyzed on the basis of the market scenario in the major countries of the regions to provide a deeper understanding of the market.

Benefits of the Global CRISPR Report:

To learn more about the report, visit @ https://reportsglobe.com/product/global-crispr-market/

Thank you for reading our report. To learn more about report details or for customization information, please contact us. Our team will ensure that the report is customized according to your requirements.

How Reports Globe is different than other Market Research Providers

The inception of Reports Globe has been backed by providing clients with a holistic view of market conditions and future possibilities/opportunities to reap maximum profits out of their businesses and assist in decision making. Our team of in-house analysts and consultants works tirelessly to understand your needs and suggest the best possible solutions to fulfill your research requirements.

Our team at Reports Globe follows a rigorous process of data validation, which allows us to publish reports from publishers with minimum or no deviations. Reports Globe collects, segregates, and publishes more than 500 reports annually that cater to products and services across numerous domains.

Contact us:

Mr. Mark Willams

Account Manager

US: +1-970-672-0390

Email:[emailprotected]

Web:reportsglobe.com

See the original post:
CRISPR Market to Witness Exponential Growth by 2020-2027 | Leading Players Thermo Fisher Scientific, Editas Medicine, Caribou Biosciences, CRISPR...

Covid-19: What you need to know today – Hindustan Times

How seriously does one take Dr Li-Meng Yan? And how seriously does one take the paper Unusual Features of the Sars-CoV2 Genome Suggesting Sophisticated Laboratory Modification Rather Than Natural Evolution and Delineation of its Probable Synthetic Route, published by her and co-authors, under the aegis of the Rule of Law Society and the Rule of Law Foundation, New York, on September 14? As the title suggests, the paper claims the coronavirus was man-made, in a laboratory.

The paper was uploaded on open-source research repository Zenodo, run by CERN, and was reported by Hindustan Times on Wednesday (bit.ly/33uFyy4). It wasnt as widely reported as Dr Yans comments in Loose Women, a segment of a TV show hosted by a UK TV channel, on which she pretty much said the same thing, albeit without any of the scientific arguments -- unsubstantiated ones -- presented in the paper.

Heres what that paper claimed:

One, ZC45, a bat virus, or a closely related variant or mutant, bears a striking similarity with Sars-CoV2, as shown by genome sequencing, with a 94%-100% similarity of key viral proteins.

The spike protein of Sars-CoV2 is essentially a trimer (essentially three parts) each of which has an S1 and S2 part with a furin cleavage site at the boundary between the two. Other research has already established that the human cellular enzyme furin cleaves, or breaks, the S1 and S2 unit at the cleavage site, and that the S1 unit then attaches to the ACE receptor, another protein found on the surface of most human cells. This binding then facilitates the entry of the viral protein into human cells. The virus ability to bind with the receptor, and the presence of the cleavage site that responds to a cannon human enzyme, are the reasons Covid-19 is as infective as it is.

Click here for complete coverage of the Covid-19 pandemic

Both the furin cleavage site, and the binding ability of the spike protein with the ACE2 receptor arent natural, the paper argued.

In their preface to this scientific hypothesis, the authors also claim that the process of creating such a virus in a laboratory could take only six months. They ask for further research and investigation into the origin of the virus. Even if their hypothesis is subsequently proven erroneous, this is a recommendation that no can argue with the origin of the virus needs to be investigated, not so much to assign blame (although there will be some that too), but to prepare for the next virus and the next pandemic.

Dr Yan, currently in the US, where she fled to in late April, is a virologist who used to work at the University of Hong Kong School of Public Health, and who has for long claimed that China knew of the virus and the fact that human-to-human transmission of the infection was happening, long before it let on. Her claims on the virus being man-made are more recent.

Interestingly, a March paper in Nature titled The Proximal Origin of Sars-Cov2, authored by Kristian G Andersen of Californias Scripps Research Institute, argued, again picking on the same two distinctive features of Sars-CoV2, that the virus was natural. The viral protein showed a high affinity to bind with the receptor, they said, but this interaction wasnt ideal or optimal. In plain English this meant that if anyone had set out to engineer the virus, they would have picked the ideal binding relation, not just another optimal one. The paper also said that there were other coronaviruses that had similar cleavage sites and that this wasnt unique to Sars-CoV2.

However, the two papers differ in one significant aspect. The one published in Nature said the genetic data irrefutably show that Sars-CoV2 is not derived from any previously used virus backbone. Dr Yans said (again, without substantiation that) a genomic sequence analysis reveals that ZC45, or a closely related bat coronavirus, should be the backbone used for the creation of Sars-CoV2.

Also read|Over 5,000 Indians died in West, East Asian countries amid Covid-19 pandemic: Govt informs Parliament

Dr Yans claims are also being seen through a political lens, with scientists in the US pointing out that the two non-profits that published the paper were linked to Steve Bannon, former Trump adviser and former executive chairman of the far-right Breitbart News, casting aspersions on the studys findings.

Clearly, only further research and investigation can shed light on the origin of the virus which has thus far infected 29,927,685 and killed 942,564 around the world. India ended Wednesday with 5,115,846 cases and 83,230 deaths.

But as Vivek Wadhwa, a columnist for this paper, a top technology thinker, and distinguished fellow at Harvard Law Schools Labor and Worklife Program, said in a recent article in Foreign Policy: If genetic engineering wasnt behind this pandemic, it could very well unleash the next one. Thats because, genetic engineering with all its potential for good and bad has become democratised, Wadhwa wrote.

Thanks to a technological revolution in genetic engineering, all the tools needed to create a virus have become so cheap, simple, and readily available that any rogue scientist or college-age biohacker can use them.

The rest is here:
Covid-19: What you need to know today - Hindustan Times

Nanomedicine Seen As A Promising Approach For Diagnosis and Treatment Against COVID – PRNewswire

PLAM BEACH, Fla., Sept. 16, 2020 /PRNewswire/ --The National Institute for Health (NIH) is at the heart of the emerging and rapidly evolving war against the global pandemic. They constantly update the public on the latest information on research for a vaccine and therapies to fight the virus. A recent report from them shone the light on a specific promising therapeutic approach nanomedicine. The NIH said that nanomedicine is a promising approach fordiagnosis, treatment and prophylaxis against COVID-19. They said that: "The COVID-19pandemic caused by the newly emerged severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) puts the world in an unprecedented crisis, leaving behind huge human losses and deep socioeconomic damages. Due to the lack of specific treatment against SARS-CoV-2, effective vaccines and antiviral agents are urgently needed to properly restrain the COVID-19 pandemic. Repositioned drugs such asremdesivir have revealed a promising clinical efficacy against COVID-19. Interestingly, nanomedicine as a promising therapeutic approach could effectively help win the battle between coronaviruses and host cells."Mentioned in today's commentary include: NanoViricides, Inc. (NYSE: NNVC), Immunomedics(NASDAQ: IMMU), Gilead Sciences, Inc. (NASDAQ: GILD), Inovio Pharmaceuticals, Inc. (NASDAQ: INO), Novavax, Inc. (NASDAQ: NVAX).

Due to a lack of approved vaccines and specific treatments only preventive measures can currently be applied. Currently, development of an effective vaccine and specific treatment is the main concern for researchers worldwide to fight the current COVID-19 and any future mutations. Understanding the coronaviral genome and the processes of viral replication and pathogenesis will enable researchers to develop specific drugs and vaccines. So researchers are turning to nanomedicine, one of the most important and emerging fields of modern science.

NanoViricides, Inc. (NYSE American: NNVC) Breaking News: NanoViricides Nominates a Novel Candidate for Advancing Into Clinical Trials for Treatment of COVID-19 NanoViricides, a global leader in the development of highly effective antiviral therapies based on a novel nanomedicines platform, today announced that it has nominated a clinical drug candidate for the treatment of COVID-19, thus further advancing its COVID-19 program closer to human clinical trials.

The Company has accelerated its drug development program for COVID-19 with the goal of creating the most effective medicine to obtain regulatory approval for emergency use in the COVID-19 pandemic in the shortest timeline feasible, after achieving proof of concept of broad-spectrum anti-coronavirus effectiveness of test candidates. The Company therefore aggressively worked to harness the full power of the nanoviricides nanomedicine platform to achieve these objectives.

A curative treatment for a virus such as SARS-CoV-2 coronavirus would require a multi-faceted attack that shuts down (i) ability of the virus to infect host cells and simultaneously, (ii) ability of the virus to multiply inside the host cells. The nanoviricide platform enables direct multi-point attack on the virus that is designed to disable the virus and its ability to infect new cells. At the same time, a nanoviricide is also capable of carrying payload in its "belly" (inside the micelle) that can be chosen to affect the ability of the virus to replicate. The nanoviricide is designed to protect the payload from metabolism in circulation. Thus, the nanoviricide platform provides an important opportunity to develop a curative treatment against SARS-CoV-2, the cause of COVID-19 spectrum of pathologies.

The clinical candidate the Company has chosen is identified as NV-CoV-1-R. It is made up of a nanoviricide that we have found to possess broad-spectrum anti-coronavirus activity, now identified as NV-CoV-1, and remdesivir encapsulated inside the core of NV-CoV-1. NV-CoV-1 itself is designed to attack the virus particles themselves, and possibly would also attack infected cells that display the virus antigen S-protein, while sparing normal (uninfected) cells that do not display the S-protein. Additionally, remdesivir is widely understood to attack the replication cycle of the virus inside cells. Thus the combined attack enabled by NV-CoV-1-R on the virus could prove to be a cure for the infection and the disease, provided that the necessary dosage level can be attained without undue adverse effects. Human clinical trials will be required to determine the safety and effectiveness of NV-CoV-1-R.

Remdesivir is a well-known antiviral drug (developed by Gilead) that has been approved for emergency use treatment of SARS-CoV-2 infection or COVID-19 in several countries. NV-CoV-1 is a novel agent that is being used as an adjuvant to remdesivir in creating NV-CoV-1-R, to improve the overall effectiveness. It is well known that remdesivir suffers from rapid metabolism in circulation that breaks down the prodrug to its nucleoside form which is not readily phosphorylated. The Company anticipates that encapsulation in NV-CoV-1 may protect remdesivir from this rapid metabolism. If this happens, the effective level and stability of remdesivir in the body would increase. This increase may lead to increased effectiveness if there are no adverse effects. Such increased effectiveness, if found, may also allow reduction in the required dosage of remdesivir in the encapsulated form, i.e. as NV-CoV-1-R. In this sense, NV-CoV-1 can be viewed to act as an adjuvant that enhances the effect of remdesivir, a known antiviral against SARS-CoV-2.

"This is an extremely important milestone for the Company," said Anil R. Diwan, PhD, President and Executive Chairman of the Company, adding, "We look forward to rapid development of the IND enabling core safety pharmacology studies and, thereafter, human clinical development on an accelerated timeline in these trying times of the pandemic." Read the full press release by going to: http://www.nanoviricides.com/companynews.html

In other biotech news in the markets this week:

Immunomedics(NASDAQ: IMMU) and Gilead Sciences, Inc. (NASDAQ: GILD)recently announcedthat the companies have entered into a definitive agreement pursuant to which Gilead will acquire Immunomedics for $88.00 per share in cash. The transaction, which values Immunomedics at approximately $21 billion, was unanimously approved by both the Gilead and Immunomedics Boards of Directors and is anticipated to close during the fourth quarter of 2020.

The agreement will provide Gilead with TrodelvyTM(sacituzumab govitecan-hziy), a first-in-class Trop-2 directed antibody-drug conjugate (ADC) that was granted accelerated approval by the U.S. Food and Drug Administration (FDA) in April for the treatment of adult patients with metastatic triple-negative breast cancer (mTNBC) who have received at least two prior therapies for metastatic disease. Immunomedics plans to submit a supplemental Biologics License Application (BLA) to support full approval of Trodelvy in the United States in the fourth quarter of 2020. Immunomedics is also on track to file for regulatory approval in Europe in the first half of 2021.

"This acquisition represents significant progress in Gilead's work to build a strong and diverse oncology portfolio. Trodelvy is an approved, transformational medicine for a form of cancer that is particularly challenging to treat. We will now continue to explore its potential to treat many other types of cancer, both as a monotherapy and in combination with other treatments," said Daniel O'Day, Chairman and Chief Executive Officer, Gilead Sciences. "We look forward to welcoming the talented Immunomedics team to Gilead so we can continue to advance this important new medicine for the benefit of patients with cancer worldwide."

INOVIO (NASDAQ: INO), a biotechnology company focused on bringing to market precisely designed DNA medicines to treat and protect people from infectious diseases and cancer, recently announced that Thermo Fisher Scientific, the world leader in serving science, has signed a letter of intent to manufacture INOVIO's DNA COVID-19 vaccine candidate INO-4800.

Thermo Fisherjoins other contract development and manufacturing organizations in INOVIO's global manufacturing consortium, enabling INOVIO to potentially scale commercial production of INO-4800. With its consortium of third-party manufacturers, INOVIO plans to have 1001million doses of INO-4800 manufactured in 2021, subject to FDA approval of INO-4800 for use as a COVID-19 vaccine.Thermo Fisherplans to manufacture INO-4800 drug substance as well as perform fill and finish of INO-4800 drug product at its commercial facilities in the US. At peak capacity,Thermo Fisherprojects that it could produce at least 100 million doses of INO-4800 annually.

Novavax, Inc. (NASDAQ: NVAX), a late-stage biotechnology company developing next-generation vaccines for serious infectious diseases, recently announced an amendment to its existing agreement with Serum Institute of India Private Limited (SIIPL) under which SIIPL will also manufacture the antigen component of NVXCoV2373, Novavax' COVID19 vaccine candidate. With this agreement, Novavax increases its manufacturing capacity of NVX-CoV2373 to overtwo billion doses annually, when all planned capacity has been brought online by mid-2021. NVXCoV2373 is a stable, prefusion protein made using Novavax' recombinant protein nanoparticle technology and includes Novavax' proprietary MatrixM adjuvant.

"Today's agreement with Serum Institute enhances Novavax' commitment to equitable global delivery of our COVID-19 vaccine. With this arrangement, we have now put in place a global supply chain that includes the recently acquired Praha Vaccines and partnerships with leading biologics manufacturers, enabling production on three continents," said Stanley C. Erck, President and Chief Executive Officer of Novavax. "We continue to work with extraordinary urgency to develop our vaccine, now in Phase 2 clinical trials, and for which we anticipate starting Phase 3 efficacy trials around the world in the coming weeks."

DISCLAIMER: FN Media Group LLC (FNM), which owns and operates Financialnewsmedia.com and MarketNewsUpdates.com, is a third- party publisher and news dissemination service provider, which disseminates electronic information through multiple online media channels.FNM is NOT affiliated in any manner with any company mentioned herein. FNM and its affiliated companies are a news dissemination solutions provider and are NOT a registered broker/dealer/analyst/adviser, holds no investment licenses and may NOT sell, offer to sell or offer to buy any security.FNM's market updates, news alerts and corporate profiles are NOT a solicitation or recommendation to buy, sell or hold securities. The material in this release is intended to be strictly informational and is NEVER to be construed or interpreted as research material.All readers are strongly urged to perform research and due diligence on their own and consult a licensed financial professional before considering any level of investing in stocks. All material included herein is republished content and details which were previously disseminated by the companies mentioned in this release.FNM is not liable for any investment decisions by its readers or subscribers. Investors are cautioned that they may lose all or a portion of their investment when investing in stocks. For current services performed FNM was compensated twenty five hundred dollars for news coverage of current press release issued by NanoViricides, Inc. by a non-affiliated third party.FNM HOLDS NO SHARES OF ANY COMPANY NAMED IN THIS RELEASE.

This release contains "forward-looking statements" within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E the Securities Exchange Act of 1934, as amended and such forward-looking statements are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. "Forward-looking statements" describe future expectations, plans, results, or strategies and are generally preceded by words such as "may", "future", "plan" or "planned", "will" or "should", "expected," "anticipates", "draft", "eventually" or "projected". You are cautioned that such statements are subject to a multitude of risks and uncertainties that could cause future circumstances, events, or results to differ materially from those projected in the forward-looking statements, including the risks that actual results may differ materially from those projected in the forward-looking statements as a result of various factors, and other risks identified in a company's annual report on Form 10-K or 10-KSB and other filings made by such company with the Securities and Exchange Commission. You should consider these factors in evaluating the forward-looking statements included herein, and not place undue reliance on such statements. The forward-looking statements in this release are made as of the date hereof and FNM undertakes no obligation to update such statements.

Contact Information:Media Contact email: [emailprotected]+1(561)325-8757

SOURCE FinancialNewsMedia.com

Go here to read the rest:
Nanomedicine Seen As A Promising Approach For Diagnosis and Treatment Against COVID - PRNewswire

Healthcare Nanotechnology Market Insights Competitive Analysis and Future Demand and Revenue Forecast to 2024 | Key Companies: Amgen, Stryker, Teva…

Healthcare Nanotechnology Market2020-2025 report offerscomprehensive quantitative and qualitative market analysis. This report has been prepared under the continuous observation of the global market situation. This report has been formulated to give our clients the most up to date data and analyses of the Healthcare Nanotechnology Market. The impact on the enterprises and business development, distribution by region and global level is assessed in the report.

Top Companies are covering This Report:-

AmgenStrykerTeva PharmaceuticalsUCBRocheAbbottMerck & CoCelgeneBiogenSanofiLeadiant BiosciencesShireKyowa Hakko KirinGilead SciencesJohnson & Johnson3M CompanyEndo InternationalSmith & NephewPfizerIpsen

The research process involved the study of various factors affecting the industry such as government policy, market environment, competitive landscape, historical data, existing trends in the market, and market risks, opportunities, market barriers and challenges.

Reports Intellect projects Healthcare Nanotechnology Market based on elite players, present, past, and forecast data for the coming years which will act as a profitable guide for all the market competitors. The study includes growth trends, micro- economic and macro-economic indicators in detail and the report has been assessed with the help of PESTEL analysis and other essential analyses operating in the Healthcare Nanotechnology Market. Top-down and bottom-up approaches are used to validate the global Healthcare Nanotechnology market size and estimate the market size for Company, regions segments, product segments and Application.

Get Sample PDF Brochure @https://www.reportsintellect.com/sample-request/905451

The report offers all the essential data for players to secure a position of strength in the market, all while creating a comprehensive action plan. Our analysts here at Reports Intellect have used advanced primary and secondary research techniques to create the most up to date assessment of data on the Healthcare Nanotechnology Market which opens up a plethora of new opportunities to create new strategies to gain leverage over the competition.

Type Coverage:

NanomedicineNano Medical DevicesNano DiagnosisOthersNanomedicine has the highest percentage of revenue by type, with more than 86% in 2019.

Application Coverage:

AnticancerCNS ProductAnti-infectiveOthersAccording to the application, anticancer and CNS products accounted for 17.56% and 22.70% of the market in 2019 respectively.

Market Segment by Regions, regional analysis covers

North America Country (United States, Canada)

South America

Asia Country (China, Japan, India, Korea)

Europe Country (Germany, UK, France, Italy)

Other Country (Middle East, Africa, GCC)

Discount PDF Brochure @https://www.reportsintellect.com/discount-request/905451

Why us:

Reasons to buy:

About Us:-

Contact Us:

Sales@reportsintellect.com

PH + 1-706-996-2486

US Address:

225 Peachtree Street NE,

Suite 400,

Atlanta, GA 30303

Follow this link:
Healthcare Nanotechnology Market Insights Competitive Analysis and Future Demand and Revenue Forecast to 2024 | Key Companies: Amgen, Stryker, Teva...

Medical Biomimetics Market research, Industry Outlook, Current Trends and Forecast by 2025 – The Research Process

A detailed overview of Medical Biomimetics market with respect to the pivotal drivers influencing the revenue graph of this business sphere. The current trends of Medical Biomimetics market in conjunction with the geographical landscape, demand spectrum, remuneration scale, and growth graph of this vertical have also been included in this report.

Increasing rate of organ failure coupled with growing geriatric population base will act as growth impact rendering factors for medical biomimetics market during the forecast timeframe. As per the U.S. Census Bureau?s 2017 National Population Projections, there will be nearly 78 million people aged more than 65 years, while 76.7 million under 18 years of age in the U.S. by 2035, thereby escalating demand for biomimetics products in coming future.

High adoption of western culture, unhealthy diet and physical inactivity has led to rising incidence of cardiovascular diseases, resulting in increased demand for biomimetic cardiovascular products. Numerous applications of biomimetics in healthcare industry including fields such as dentistry, orthopedics, cardiovascular, and ophthalmology should stimulate business growth during the analysis period.

Request Sample Copy of this Report @ https://www.theresearchprocess.com/request-sample/5768

Medical Biomimetics Market will reach over USD 35 billion by 2025; as per a new research report.

Request Sample Copy of this Report @ https://www.theresearchprocess.com/request-sample/5768

Orthopedic product segment accounted for more than 30% market share in 2018 and is estimated to witness significant growth during the forecast period owing to growing demand for orthopedic prosthesis and implants. For instance, increasing number of accidents and injuries have escalated the demand for prosthetic limbs. Technological advancements including development of augment bone graft should positively impact segmental growth.

Application segment of medical biomimetics market includes plastic surgery, wound healing, tissue engineering, drug delivery and others including nanomedicine, drug discovery, enzymatic modification and medical engineering. Plastic surgery application segment will witness 6.3% CAGR over the coming years due to wide application of biomimetics in plastic surgery for scaffold formation. It is also used in craniofacial surgery for restoration of facial aesthetics, function and form.

Increasing R&D activities pertaining to development of innovative biomimetic products along with advancements in nanotechnology, tissue engineering utilizing biomimetics technology should positively impact industry expansion. However, high capital investment in R&D along with stringent regulations will hinder industry growth during the forecast timeframe.

Germany medical biomimetics market dominated European region in 2018 and is anticipated to grow at 5.8% during the forecast period. High technological adoption, rising geriatric population prone to suffer from organ failure and increasing incidence of ophthalmology, orthopedic and cardiovascular disorders in the country are driving factors for Germany medical biomimetics market.

Saudi Arabia medical biomimetics market will witness 5.2% CAGR during the forecast timeframe. Growing demand and adoption of cosmetic surgical procedures among women, technological advancements and rising awareness should drive Saudi Arabia medical biomimetics industry during the analysis period. Rising incidence of coronary heart disease coupled with growing uptake of unhealthy habits such as alcohol consumption and tobacco smoking will augment demand for biomimetic products in the region.

Major Highlights from Table of contents are listed below for quick lookup into Medical Biomimetics Market report

Chapter 1. Competitive Landscape

Chapter 2. Company Profiles

Chapter 3. Methodology & Scope

Chapter 4. Executive Summary

Chapter 5. Medical Biomimetics industryInsights

Request Customization on This Report @ https://www.theresearchprocess.com/request-for-customization/5768

Here is the original post:
Medical Biomimetics Market research, Industry Outlook, Current Trends and Forecast by 2025 - The Research Process

What are the Signs & Symptoms of Endometriosis? – HealthCentral.com

If youre a woman, youre probably intimately familiar with the abdominal pain and cramps that pop up once a month during your period. Generations of women have been taught that its normal to feel menstrual painbut a new wave of doctors say thats not always the case: Sometimes, pelvic pain can be a sign of a serious condition called endometriosis, and if you dont address it quickly, your future fertility could be at risk. These are some of the signs and symptoms that something more than just period pain is going on.

To understand endometriosis, first you need to know about the endometrium: Thats the lining inside the uterus that builds up once a month to allow for the implantation of a fertilized egg in the womb. If theres no fertilized egg, theres no need for a cushy lining, so the body sheds that layeralso know as having your period if youre a woman. Whats shed is a mixture of blood, vaginal secretions, and endometrial cells.

But sometimes, the blood flow gets mixed up, and instead of flowing out, it flows up, going back through the fallopian tubes and into the pelvis. Endometrial cells that mistakenly ended up in the pelvis can attach onto its walls, as well as the outside of the uterus, the fallopian tubes, or any of the organs within the pelvis. Those adventurous cells arent where theyre supposed to be, but they still try to perform the task they were designed for, and that is to collect blood to form a lining and release the blood if theres no baby on board.

Thats what endometriosis is: The growth of endometrial cells and development of thick tissue outside of the uterus that can lead to inflammation, lesions, and scarring. This tissue can grow on other organs, reducing blood flow and raising the risk of fertility issues. Endometriosis can cause intense painor none at all.

The biggest risk factor for this condition is being female (not much you can do there!). There also seems to be a genetic component involved, so if your mother, aunt, or sisters have endometriosis, you have a higher likelihood of getting it, too.

Experts estimate that 11% of reproductive-age women have endometriosis worldwide, yet here in the U.S., it can take up seven to 12 years for a proper diagnosis. That decade of pain can be attributed to a mix of factors, including limited access to care, a stigma around pelvic pain and menstruation-related complaints, and doctors who dont fully understand how to treat it.

Experts suspect endometriosis is caused by something know as retrograde menstruation. This is when menstrual fluid (blood, vaginal fluid, and endometrial cells) flows upwards rather than down and out of the body. In retrograde menstruation, the fluid is released into the pelvic cavity, overwhelming the bodys ability to remove it. This gives the endometrial cells the opportunity to find a new home. And thats the start of endometriosis.

Additionally, endometriosis can happen when endometrial cells are released into the abdomen during a surgery, such as a c-section. There are also theories that involve cells outside of the uterus mimicking endometrial cells when theyre activated by certain hormones, like estrogen.

For women who have severe cases of endometriosis, their main symptom is pain which can express itself in several different ways. Heres what to look for.

Chronic pelvic pain: There may be dull cramping throughout a womans cycle, not only when she is bleeding. Those who suffer from chronic pelvic pain (40% to 50% of those with endometriosis) often report that it gets worse when they have their period.

Constipation: If endometriosis occurs on the bowels or lower intestine, it can lead to constipation.

Heavy menstrual bleeding: Symptoms of so-called menorrhagia can include needing to use double sanitary protection (like a tampon and a pad), bleeding for more than seven days, passing blood clots larger than a quarter, and soaking through at least one pad or tampon every hour for several hours. Drop everything and go to the doctor ASAP if you have menstrual bleeding so bad that youre soaking through one pad or tampon every hour for more than two hours, bleeding between periods, or bleeding post-menopause. These can be symptoms of endometriosis, but also symptoms of other issues, including endometrial cancer.

Infertility: Between 30% and 50% of women who have endometriosis suffer from infertility issues. The causes are still being debated, but it could be that the endometriosis messes with the jobs of the ovaries and fallopian tubes. It could also be due to endocrine (hormone) or ovulatory disorders which interfere with the release and fertilization of healthy eggs. Or the normal shedding of the endometrial layer in the uterus is disrupted if endometriosis is present, and that causes infertility.

Painful sex: Between 40% and 50% of women with endometriosis report having deep dyspareunia, which is the fancy term for painful sex during deep penetration. So how do you know if pain during sex is related to endometriosis? If you have a burning sensation when your partner is first entering you, thats not probably endometriosis. If it is a knife-stabbing feeling when a partner is thrusting deeper, thats a red flag for the condition.

Sharp lower abdominal pain: This can be caused by an ovarian cyst that started as endometriosis. It can also be caused by endometriosis that attaches itself to two different organs, like an ovary and the large bowel, acting like connective tissue that binds these organs to each other. When thats jostled around, say during sex or a bowel movement, it can cause pain.

Painful urination: If endometriosis shows up outside the bladder, it can make urination painful, or blood can show up in the urine.

Severe cramping: Known as dysmenorrhea, this affects 60% to 80% of women with endometriosis. To expel the endometrial lining, the uterus contracts. What triggers those uterine contractions are prostaglandins, which are hormone-like compounds that can cause pain and inflammation. More prostaglandins are linked to more painful menstrual cramps, and endometriosis is linked with a higher level of prostaglandins.

If youre saying to yourself: Wow, it wouldnt dawn on me to go see my gynecologist if Im having poop problemsId see a gastroenterologist! youve now identified one of the challenges with endometriosis. Because of the nature of the disease, its symptoms can cross over into other conditions, making it hard to get to the root of the issue. Without a specific screening test for endometriosis, it may take some trial and error before you receive a correct diagnosis.

Despite these symptoms, 20% to 25% of endometriosis patients are asymptomatic. For them, the discovery often comes when theyre tryingand failingto get pregnant. Still, it is definitely possible to get pregnant if you have endometriosis, and its something you and a reproductive endocrinologist and fertility specialist can discuss.

Asymptomatic patients may also learn about their endometriosis if the tissue mass gets very large and leads to excessive bloating. Other women find out when they have pelvic surgery for something elsesuch as a tubal ligation, or to have an appendix removedand the surgeon sees the endometriosis.

Before we get into the nitty gritty, its worth noting that the prevailing wisdom dictates that doctors begin treating endometriosis before theres a definite diagnosis. Thats because the only way to be sure that its present is to do a laparoscopy, a minimally invasive surgery in which a long thin camera and other tools are inserted into the pelvis through small incisions in the abdomen, and tissue samples are taken and studied by a pathologist. The procedure is expensive and time-consuming, so doctors may sometimes decide to begin treatment if all other indications are for endometriosis.

So what might some of those treatments be?

The first line of defense is NSAIDs, or nonsteroidal anti-inflammatory drugs, which block the bodys production of the hormonal compound prostaglandin, thus cutting down on pain, inflammation, and cramping. NSAIDs are most effective if you start to take them before your period starts. Talk to your doctor about dosage. Dont take more than is listed on the label unless directed by your doc, though he or she may want to bump you up to the prescription type.

Contraceptives that contain hormones, such as the pill, patch, ring, shots, or a hormonal IUD can treat endometriosis by managing a womans cycle or eliminating menses altogether.

A doctor may also opt to put you on a short stint of a nonsteroidal aromatase inhibitor, which is a class of drugs that prevents the cells in the body from making estrogen or by suppressing estrogen production. It essentially creates a menopause-like state. Doctors are wary of using it long-term because, down the road, estrogen suppression can lead to issues like osteoporosis, heart disease, and cognitive decline. But in some cases, turning off the estrogen gives the body time to clean out the endometriosis.

If medical remedies dont work, surgerys an option. Doctors typically do minimally invasive surgery and either cut out or laser off the endometriosis that they see. The good news: It can provide immediate relief of the symptoms. Bad news: For 40% to 80% of women, surgery doesnt provide a total cure, and pain returns within two years of the procedure. This happens because there can be areas of endometriosis so small that the surgeon missed them.

Beyond meds and surgery, researchers are investigating the role genetics play in endometriosis in hopes that it can them predict who will develop it, and aid in the creation of highly effective treatments, too. In the meantime, lifestyle changes may also help control the condition.

For example, we know that endometriosis is an inflammatory disease, and that inflammation can exacerbate painful symptoms. So reducing the amount of inflammatory foods (such as red meat and alcohol) in your diet can help, as can adding in anti-inflammatory foods like salmon, nuts, and olive oil.

Whats more, exercisesomething you may feel challenged to do when dealing with chronic painmay help to ease some symptoms, like cramping and bloating. You dont have to go all-in on marathon running or kickboxing to see a positive effect: Just 30 minutes of moderate exercise daily, like walking or jogging, can help ease your symptoms while improving your overall health and fitness.

See more here:
What are the Signs & Symptoms of Endometriosis? - HealthCentral.com